%% This BibTeX bibliography file was created using BibDesk.
%% https://bibdesk.sourceforge.io/

%% Created for Francois Collin at 2020-09-29 16:19:22 -0700 


%% Saved with string encoding Unicode (UTF-8) 



@article{Molania:2019aa,
	Abstract = {The Nanostring nCounter gene expression assay uses molecular barcodes and single molecule imaging to detect and count hundreds of unique transcripts in a single reaction. These counts need to be normalized to adjust for the amount of sample, variations in assay efficiency and other factors. Most users adopt the normalization approach described in the nSolver analysis software, which involves background correction based on the observed values of negative control probes, a within-sample normalization using the observed values of positive control probes and normalization across samples using reference (housekeeping) genes. Here we present a new normalization method, Removing Unwanted Variation-III (RUV-III), which makes vital use of technical replicates and suitable control genes. We also propose an approach using pseudo-replicates when technical replicates are not available. The effectiveness of RUV-III is illustrated on four different datasets. We also offer suggestions on the design and analysis of studies involving this technology.},
	An = {31114909},
	Author = {Molania, Ramyar and Gagnon-Bartsch, Johann A and Dobrovic, Alexander and Speed, Terence P},
	Date = {2019/07/09},
	Date-Added = {2020-09-29 16:19:12 -0700},
	Date-Modified = {2020-09-29 16:19:12 -0700},
	Db = {PubMed},
	Doi = {10.1093/nar/gkz433},
	Isbn = {1362-4962; 0305-1048},
	J2 = {Nucleic Acids Res},
	Journal = {Nucleic acids research},
	Keywords = {Adenocarcinoma of Lung/genetics/metabolism; Dendritic Cells/metabolism; Gene Expression Profiling/*methods; Humans; Inflammatory Bowel Diseases/genetics/metabolism; Lung Neoplasms/genetics/metabolism; Lymphocyte Activation/genetics; Single Molecule Imaging},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614807/},
	La = {eng},
	Month = {07},
	Number = {12},
	Pages = {6073--6083},
	Publisher = {Oxford University Press},
	Title = {A new normalization for Nanostring nCounter gene expression data},
	Ty = {JOUR},
	U1 = {31114909{$[$}pmid{$]$}},
	U2 = {PMC6614807{$[$}pmcid{$]$}},
	U4 = {5494770{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/31114909},
	Volume = {47},
	Year = {2019},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/31114909},
	Bdsk-Url-2 = {https://doi.org/10.1093/nar/gkz433}}

@article{Li:2018aa,
	Abstract = {Breast cancer (BC) is increasing in incidence and resistance to treatment worldwide. The challenges in limited therapeutic options and poor survival outcomes in BC subtypes persist because of its molecular heterogeneity and resistance to standard endocrine therapy. Recently, high throughput RNA sequencing (RNA-seq) has been used to identify biomarkers of disease progression and signaling pathways that could be amenable to specific therapies according to the BC subtype. However, there is no single generally accepted pipeline for the analysis of RNA-seq data in biomarker discovery due, in part, to the needs of simultaneously satisfying constraints of sensitivity and specificity. We proposed a combined approach using gene-wise normalization, UQ-pgQ2, followed by a Wald test from DESeq2. Our approach improved the analysis based on within-group comparisons in terms of the specificity when applied to publicly available RNA-seq BC datasets. In terms of identifying differentially expressed genes (DEGs), we combined an optimized log2 fold change cutoff with a nominal false discovery rate of 0.05 to further minimize false positives. Using this method in the analysis of two GEO BC datasets, we identified 797 DEGs uniquely expressed in triple negative BC (TNBC) and significantly associated with T cell and immune-related signaling, contributing to the immunotherapeutic efficacy in TNBC patients. In contrast, we identified 1403 DEGs uniquely expressed in estrogen positive and HER2 negative BC (ER+HER2-BC) and significantly associated with eicosanoid, notching and FAK signaling while a common set of genes was associated with cellular growth and proliferation. Thus, our approach to control for false positives identified two distinct gene expression profiles associated with these two subtypes of BC which are distinguishable by their molecular and functional attributes.},
	An = {30089167},
	Author = {Li, Xiaohong and Rouchka, Eric C and Brock, Guy N and Yan, Jun and O'Toole, Timothy E and Tieri, David A and Cooper, Nigel G F},
	Date = {2018/08/08},
	Date-Added = {2020-09-03 08:30:10 -0700},
	Date-Modified = {2020-09-03 08:30:10 -0700},
	Db = {PubMed},
	Doi = {10.1371/journal.pone.0201813},
	Isbn = {1932-6203},
	J2 = {PLoS One},
	Journal = {PloS one},
	Keywords = {Biomarkers, Tumor/genetics/metabolism; Breast Neoplasms/classification/genetics/*metabolism; Computational Biology; Gene Expression Regulation, Neoplastic; Humans; RNA, Messenger/metabolism; Sequence Analysis, RNA/*methods},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082555/},
	La = {eng},
	Month = {08},
	Number = {8},
	Pages = {e0201813--e0201813},
	Publisher = {Public Library of Science},
	Title = {A combined approach with gene-wise normalization improves the analysis of RNA-seq data in human breast cancer subtypes},
	Ty = {JOUR},
	U1 = {30089167{$[$}pmid{$]$}},
	U2 = {PMC6082555{$[$}pmcid{$]$}},
	U4 = {PONE-D-18-01961{$[$}PII{$]$}},
	Url = {https://www.ncbi.nlm.nih.gov/pubmed/30089167},
	Volume = {13},
	Year = {2018},
	Bdsk-Url-1 = {https://www.ncbi.nlm.nih.gov/pubmed/30089167},
	Bdsk-Url-2 = {https://doi.org/10.1371/journal.pone.0201813}}

@article{Robinson:2010aa,
	Abstract = {A novel and empirical method for normalization of RNA-seq data is presented},
	An = {PMC2864565},
	Author = {Robinson, Mark D and Oshlack, Alicia},
	Date-Added = {2020-08-29 15:05:59 -0700},
	Date-Modified = {2020-08-29 15:05:59 -0700},
	Db = {PMC},
	Doi = {10.1186/gb-2010-11-3-r25},
	Isbn = {1465-6906; 1465-6914},
	J1 = {Genome Biol},
	Journal = {Genome Biology},
	Number = {3},
	Pages = {R25--R25},
	Publisher = {BioMed Central},
	Title = {A scaling normalization method for differential expression analysis of RNA-seq data},
	Ty = {JOUR},
	U1 = {gb-2010-11-3-r25{$[$}PII{$]$}; 20196867{$[$}pmid{$]$}},
	Url = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864565/},
	Volume = {11},
	Year = {2010},
	Year1 = {2010/03/02},
	Year2 = {2009/11/19/received},
	Year3 = {2010/01/28/revised},
	Year4 = {2010/03/02/accepted},
	Bdsk-File-1 = {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},
	Bdsk-Url-1 = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2864565/},
	Bdsk-Url-2 = {http://dx.doi.org/10.1186/gb-2010-11-3-r25}}

@article{Holloway:2006aa,
	Abstract = {BACKGROUND: Concerns are often raised about the accuracy of microarray technologies and the degree of cross-platform agreement, but there are yet no methods which can unambiguously evaluate precision and sensitivity for these technologies on a whole-array basis. RESULTS: A methodology is described for evaluating the precision and sensitivity of whole-genome gene expression technologies such as microarrays. The method consists of an easy-to-construct titration series of RNA samples and an associated statistical analysis using non-linear regression. The method evaluates the precision and responsiveness of each microarray platform on a whole-array basis, i.e., using all the probes, without the need to match probes across platforms. An experiment is conducted to assess and compare four widely used microarray platforms. All four platforms are shown to have satisfactory precision but the commercial platforms are superior for resolving differential expression for genes at lower expression levels. The effective precision of the two-color platforms is improved by allowing for probe-specific dye-effects in the statistical model. The methodology is used to compare three data extraction algorithms for the Affymetrix platforms, demonstrating poor performance for the commonly used proprietary algorithm relative to the other algorithms. For probes which can be matched across platforms, the cross-platform variability is decomposed into within-platform and between-platform components, showing that platform disagreement is almost entirely systematic rather than due to measurement variability. CONCLUSION: The results demonstrate good precision and sensitivity for all the platforms, but highlight the need for improved probe annotation. They quantify the extent to which cross-platform measures can be expected to be less accurate than within-platform comparisons for predicting disease progression or outcome.},
	Address = {London},
	An = {PMC1664592},
	Author = {Holloway, Andrew J and Oshlack, Alicia and Diyagama, Dileepa S and Bowtell, David DL and Smyth, Gordon K},
	Date-Added = {2020-08-28 19:09:37 -0700},
	Date-Modified = {2020-08-28 19:09:37 -0700},
	Db = {PMC},
	Doi = {10.1186/1471-2105-7-511},
	Isbn = {1471-2105},
	J1 = {BMC Bioinformatics},
	Journal = {BMC Bioinformatics},
	Pages = {511--511},
	Publisher = {BioMed Central},
	Title = {Statistical analysis of an RNA titration series evaluates microarray precision and sensitivity on a whole-array basis},
	Ty = {JOUR},
	U1 = {1471-2105-7-511{$[$}PII{$]$}; 17118209{$[$}pmid{$]$}},
	Url = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1664592/},
	Volume = {7},
	Year = {2006},
	Year1 = {2006/11/22},
	Year2 = {2006/06/27/received},
	Year3 = {2006/11/22/accepted},
	Bdsk-Url-1 = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1664592/},
	Bdsk-Url-2 = {https://doi.org/10.1186/1471-2105-7-511}}

@article{Law:2018aa,
	Author = {Law, CW and Alhamdoosh, M and Su, S and Dong, X and Tian, L and Smyth, GK and Ritchie, ME},
	Date = {2018},
	Date-Added = {2020-08-27 09:51:47 -0700},
	Date-Modified = {2020-08-29 14:43:39 -0700},
	Journal = {F1000Research},
	Number = {1408},
	Title = {RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR [version 3; peer review: 3 approved]},
	Type = {10.12688/f1000research.9005.3},
	Url = {https://dx.doi.org/10.12688%2Ff1000research.9005.3},
	Volume = {5},
	Year = {2018},
	Bdsk-Url-1 = {http://openr.es/e5n}}

@article{Storey:2003aa,
	Abstract = {With the increase in genomewide experiments and the sequencing of multiple genomes, the analysis of large data sets has become commonplace in biology. It is often the case that thousands of features in a genomewide data set are tested against some null hypothesis, where a number of features are expected to be significant. Here we propose an approach to measuring statistical significance in these genomewide studies based on the concept of the false discovery rate. This approach offers a sensible balance between the number of true and false positives that is automatically calibrated and easily interpreted. In doing so, a measure of statistical significance called the q value is associated with each tested feature. The q value is similar to the well known p value, except it is a measure of significance in terms of the false discovery rate rather than the false positive rate. Our approach avoids a flood of false positive results, while offering a more liberal criterion than what has been used in genome scans for linkage.},
	An = {12883005},
	Author = {Storey, John D and Tibshirani, Robert},
	Date = {2003/08/05},
	Date-Added = {2020-06-17 13:06:39 -0700},
	Date-Modified = {2020-06-17 13:06:39 -0700},
	Db = {PubMed},
	Doi = {10.1073/pnas.1530509100},
	Et = {2003/07/25},
	Isbn = {0027-8424; 1091-6490},
	J2 = {Proc Natl Acad Sci U S A},
	Journal = {Proceedings of the National Academy of Sciences of the United States of America},
	Keywords = {Algorithms; Alternative Splicing; Animals; Binding Sites; Exons; Gene Expression Regulation; Genetic Linkage; *Genetic Techniques; *Genome; Humans; Oligonucleotide Array Sequence Analysis/methods; Statistics as Topic; Transcription, Genetic},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC170937/},
	La = {eng},
	Month = {08},
	Number = {16},
	Pages = {9440--9445},
	Publisher = {National Academy of Sciences},
	Title = {Statistical significance for genomewide studies},
	Ty = {JOUR},
	U1 = {12883005{$[$}pmid{$]$}},
	U2 = {PMC170937{$[$}pmcid{$]$}},
	U4 = {1530509100{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/12883005},
	Volume = {100},
	Year = {2003},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/12883005},
	Bdsk-Url-2 = {https://doi.org/10.1073/pnas.1530509100}}

@article{NIST:2374,
	Author = {NIST SRM 2374},
	Date-Added = {2020-06-17 10:59:15 -0700},
	Date-Modified = {2020-06-17 11:00:29 -0700},
	Journal = {https://www-s.nist.gov/srmors/ certificates/2374.pdf},
	Title = {Certificate of Analysis},
	Year = {2013}}

@article{Baker:2005aa,
	Abstract = {Standard controls and best practice guidelines advance acceptance of data from research, preclinical and clinical laboratories by providing a means for evaluating data quality. The External RNA Controls Consortium (ERCC) is developing commonly agreed-upon and tested controls for use in expression assays, a true industry-wide standard control.},
	Address = {Illumina, Inc., 9885 Towne Centre Drive, San Diego, California 92121, USA.},
	Author = {Baker, Shawn C and Bauer, Steven R and Beyer, Richard P and Brenton, James D and Bromley, Bud and Burrill, John and Causton, Helen and Conley, Michael P and Elespuru, Rosalie and Fero, Michael and Foy, Carole and Fuscoe, James and Gao, Xiaolian and Gerhold, David Lee and Gilles, Patrick and Goodsaid, Federico and Guo, Xu and Hackett, Joe and Hockett, Richard D and Ikonomi, Pranvera and Irizarry, Rafael A and Kawasaki, Ernest S and Kaysser-Kranich, Tamma and Kerr, Kathleen and Kiser, Gretchen and Koch, Walter H and Lee, Kathy Y and Liu, Chunmei and Liu, Z Lewis and Lucas, Anne and Manohar, Chitra F and Miyada, Garry and Modrusan, Zora and Parkes, Helen and Puri, Raj K and Reid, Laura and Ryder, Thomas B and Salit, Marc and Samaha, Raymond R and Scherf, Uwe and Sendera, Timothy J and Setterquist, Robert A and Shi, Leming and Shippy, Richard and Soriano, Jesus V and Wagar, Elizabeth A and Warrington, Janet A and Williams, Mickey and Wilmer, Frederike and Wilson, Mike and Wolber, Paul K and Wu, Xiaoning and Zadro, Renata},
	Cn = {External RNA Controls, Consortium},
	Crdt = {2005/09/24 09:00},
	Date = {2005 Oct},
	Date-Added = {2020-06-17 10:57:29 -0700},
	Date-Modified = {2020-06-17 10:57:29 -0700},
	Dcom = {20051109},
	Doi = {10.1038/nmeth1005-731},
	Edat = {2005/09/24 09:00},
	Issn = {1548-7091 (Print); 1548-7091 (Linking)},
	Jid = {101215604},
	Journal = {Nat Methods},
	Jt = {Nature methods},
	Language = {eng},
	Lr = {20071115},
	Mh = {Animals; Gene Expression Profiling/*standards; Guidelines as Topic; Humans; Mice; Oligonucleotide Array Sequence Analysis/*standards; Quality Control; RNA, Messenger/*analysis; Rats},
	Mhda = {2005/11/10 09:00},
	Month = {Oct},
	Number = {10},
	Own = {NLM},
	Pages = {731--734},
	Phst = {2005/09/24 09:00 {$[$}pubmed{$]$}; 2005/11/10 09:00 {$[$}medline{$]$}; 2005/09/24 09:00 {$[$}entrez{$]$}},
	Pii = {nmeth1005-731},
	Pl = {United States},
	Pmid = {16179916},
	Pst = {ppublish},
	Pt = {Journal Article},
	Rn = {0 (RNA, Messenger)},
	Sb = {IM},
	Status = {MEDLINE},
	Title = {The External RNA Controls Consortium: a progress report.},
	Volume = {2},
	Year = {2005},
	Bdsk-Url-1 = {https://doi.org/10.1038/nmeth1005-731}}

@article{Munro:2014aa,
	Abstract = {There is a critical need for standard approaches to assess, report and compare the technical performance of genome-scale differential gene expression experiments. Here we assess technical performance with a proposed standard 'dashboard' of metrics derived from analysis of external spike-in RNA control ratio mixtures. These control ratio mixtures with defined abundance ratios enable assessment of diagnostic performance of differentially expressed transcript lists, limit of detection of ratio (LODR) estimates and expression ratio variability and measurement bias. The performance metrics suite is applicable to analysis of a typical experiment, and here we also apply these metrics to evaluate technical performance among laboratories. An interlaboratory study using identical samples shared among 12 laboratories with three different measurement processes demonstrates generally consistent diagnostic power across 11 laboratories. Ratio measurement variability and bias are also comparable among laboratories for the same measurement process. We observe different biases for measurement processes using different mRNA-enrichment protocols.},
	Address = {1{$]$} National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, USA [2] Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California 94305, USA.; National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, USA.; 1{$]$} National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, USA [2] Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California 94305, USA.; Interdisciplinary Centre for Bioinformatics, University of Leipzig, H{\"a}rtelstrasse 16-18, 04107 Leipzig, Germany.; Institute of Bioinformatics, Johannes Kepler University, Altenberger Str. 69, 4040 Linz, Austria.; Computational Genomics Program, Principe Felipe Research Center, Avd Eduardo Primo Y{\'u}fera 3, 46012 Valencia, Spain.; 1{$]$} Computational Genomics Program, Principe Felipe Research Center, Avd Eduardo Primo Y{\'u}fera 3, 46012 Valencia, Spain [2] CIBER de Enfermedades Raras (CIBERER) and Functional Genomics Node, INB., Valencia, Spain.; ecSeq Bioinformatics, Brandvorwerkstrasse 43, 04275 Leipzig, Germany.; Institute of Bioinformatics, Johannes Kepler University, Altenberger Str. 69, 4040 Linz, Austria.; National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, USA.; Genomics Core Facility, Feinberg School of Medicine, Northwestern University, Tarry building 2-757, 300 E. Superior St. Chicago, Illinois 60611, USA.; 1{$]$} Chair of Bioinformatics, Boku University Vienna, Muthgasse 18, Vienna 1190, Austria [2] University of Warwick, Coventry CV4 7AL, UK.; Chair of Bioinformatics, Boku University Vienna, Muthgasse 18, Vienna 1190, Austria.; Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medical College, 1305 York Avenue, Room Y13-04, Box 140, New York, New York 10021, USA.; 1{$]$} Division of Bioinformatics, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia [2] Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia.; Nationwide Children's Hospital, Columbus, Ohio 43205, USA.; National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, USA.; Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medical College, 1305 York Avenue, Room Y13-04, Box 140, New York, New York 10021, USA.; 1{$]$} CIBER de Enfermedades Raras (CIBERER) and Functional Genomics Node, INB., Valencia, Spain [2] Medical Genome Project, Genomics and Bioinformatics Platform of Andalusia, c/ Albert Einstein s/n, 41092 Sevilla, Spain.; Thermo Fisher Scientific, Research \&Development, 2170 Woodward Street, Austin, Texas 78744, USA.; State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, Schools of Life Sciences and Pharmacy, Fudan University, Shanghai 201203, China.; 1{$]$} Division of Bioinformatics, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia [2] Department of Computing and Information Systems, The University of Melbourne, Parkville, Victoria 3010, Australia.; 1{$]$} Division of Bioinformatics, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3052, Australia [2] Department of Mathematics and Statistics, The University of Melbourne, Parkville, Victoria 3010, Australia.; Chair of Bioinformatics, Boku University Vienna, Muthgasse 18, Vienna 1190, Austria.; National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, USA.; National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, USA.; Division of Microbiology and Molecular Genetics, Center for Genomics, School of Medicine, Loma Linda University, Loma Linda, California 92350, USA.; Research Informatics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.; National Center for Toxicological Research, Food and Drug Administration, 3900 NCTR Road, Jefferson, Arkansas 72079, USA.; Biomedical Informatics Research Center, Marshfield Clinic Research Foundation, 1000 N Oak Avenue, Marshfield, Wisconsin 54449, USA.; Research Informatics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.; State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, Schools of Life Sciences and Pharmacy, Fudan University, Shanghai 201203, China.; 1{$]$} National Institute of Standards and Technology, 100 Bureau Drive, Gaithersburg, Maryland 20899, USA [2] Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California 94305, USA.},
	Author = {Munro, Sarah A and Lund, Steven P and Pine, P Scott and Binder, Hans and Clevert, Djork-Arn{\'e} and Conesa, Ana and Dopazo, Joaquin and Fasold, Mario and Hochreiter, Sepp and Hong, Huixiao and Jafari, Nadereh and Kreil, David P and {\L}abaj, Pawe{\l}P and Li, Sheng and Liao, Yang and Lin, Simon M and Meehan, Joseph and Mason, Christopher E and Santoyo-Lopez, Javier and Setterquist, Robert A and Shi, Leming and Shi, Wei and Smyth, Gordon K and Stralis-Pavese, Nancy and Su, Zhenqiang and Tong, Weida and Wang, Charles and Wang, Jian and Xu, Joshua and Ye, Zhan and Yang, Yong and Yu, Ying and Salit, Marc},
	Crdt = {2014/09/26 06:00},
	Date = {2014},
	Date-Added = {2020-06-17 10:06:24 -0700},
	Date-Modified = {2020-06-17 10:06:24 -0700},
	Dcom = {20151028},
	Dep = {20140925},
	Doi = {10.1038/ncomms6125},
	Edat = {2014/09/26 06:00},
	Issn = {2041-1723 (Electronic); 2041-1723 (Linking)},
	Jid = {101528555},
	Journal = {Nat Commun},
	Jt = {Nature communications},
	Language = {eng},
	Lid = {10.1038/ncomms6125 {$[$}doi{$]$}},
	Lr = {20140926},
	Mh = {Gene Expression Profiling/*methods/standards; Humans; RNA, Messenger/*genetics; Reference Standards; Reproducibility of Results},
	Mhda = {2015/10/29 06:00},
	Month = {Sep},
	Own = {NLM},
	Pages = {5125},
	Phst = {2014/08/11 00:00 {$[$}received{$]$}; 2014/09/01 00:00 {$[$}accepted{$]$}; 2014/09/26 06:00 {$[$}entrez{$]$}; 2014/09/26 06:00 {$[$}pubmed{$]$}; 2015/10/29 06:00 {$[$}medline{$]$}},
	Pii = {ncomms6125},
	Pl = {England},
	Pmid = {25254650},
	Pst = {epublish},
	Pt = {Journal Article; Research Support, Non-U.S. Gov't},
	Rn = {0 (RNA, Messenger)},
	Sb = {IM},
	Si = {GEO/GSE46876; GEO/GSE47792},
	Status = {MEDLINE},
	Title = {Assessing technical performance in differential gene expression experiments with external spike-in RNA control ratio mixtures.},
	Volume = {5},
	Year = {2014},
	Bdsk-Url-1 = {https://doi.org/10.1038/ncomms6125}}

@article{Liu:2015ab,
	Abstract = {Heart failure is a complex clinical syndrome and has become the most common reason for adult hospitalization in developed countries. Two subtypes of heart failure, ischemic heart disease (ISCH) and dilated cardiomyopathy (DCM), have been studied using microarray platforms. However, microarray has limited resolution. Here we applied RNA sequencing (RNA-Seq) to identify gene signatures for heart failure from six individuals, including three controls, one ISCH and two DCM patients. Using genes identified from this small RNA-Seq dataset, we were able to accurately classify heart failure status in a much larger set of 313 individuals. The identified genes significantly overlapped with genes identified via genome-wide association studies for cardiometabolic traits and the promoters of those genes were enriched for binding sites for transcriptions factors. Our results indicate that it is possible to use RNA-Seq to classify disease status for complex diseases such as heart failure using an extremely small training dataset.},
	An = {25528681},
	Author = {Liu, Yichuan and Morley, Michael and Brandimarto, Jeffrey and Hannenhalli, Sridhar and Hu, Yu and Ashley, Euan A and Tang, W H Wilson and Moravec, Christine S and Margulies, Kenneth B and Cappola, Thomas P and Li, Mingyao and MAGNet consortium},
	Date = {2015/02/},
	Date-Added = {2020-06-17 07:22:14 -0700},
	Date-Modified = {2020-06-17 07:22:14 -0700},
	Db = {PubMed},
	Doi = {10.1016/j.ygeno.2014.12.002},
	Et = {2014/12/17},
	Isbn = {1089-8646; 0888-7543},
	J2 = {Genomics},
	Journal = {Genomics},
	Keywords = {Disease classification; Heart Failure; RNA-seq; Cardiomyopathy, Dilated/*genetics; Genome-Wide Association Study; Heart Failure/*genetics/metabolism; Heart Ventricles/*metabolism; Humans; Myocardial Ischemia/*genetics; Promoter Regions, Genetic; Sequence Analysis, RNA/methods; Transcription Factors/metabolism; *Transcriptome},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684258/},
	La = {eng},
	Month = {02},
	Number = {2},
	Pages = {83--89},
	Title = {RNA-Seq identifies novel myocardial gene expression signatures of heart failure},
	Ty = {JOUR},
	U1 = {25528681{$[$}pmid{$]$}},
	U2 = {PMC4684258{$[$}pmcid{$]$}},
	U4 = {S0888-7543(14)00268-7{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/25528681},
	Volume = {105},
	Year = {2015},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/25528681},
	Bdsk-Url-2 = {https://doi.org/10.1016/j.ygeno.2014.12.002}}

@article{Li:2016aa,
	Abstract = {We characterized mRNA expression profiles in normal and psoriatic human dermal mesenchymal stem cells (DMSCs) to provide a reference for future investigation of differential gene expression in DMSCs.},
	Author = {Li, Junqin and Hou, Ruixia and Niu, Xuping and Liu, Ruifeng and Wang, Qiang and Wang, Chunfang and Li, Xinhua and Hao, Zhongping and Yin, Guohua and Zhang, Kaiming},
	Da = {2016/01/01},
	Date-Added = {2020-06-17 07:21:58 -0700},
	Date-Modified = {2020-06-17 07:21:58 -0700},
	Doi = {10.1007/s10529-015-1963-5},
	Id = {Li2016},
	Isbn = {1573-6776},
	Journal = {Biotechnology Letters},
	Number = {1},
	Pages = {33--41},
	Title = {Comparison of microarray and RNA-Seq analysis of mRNA expression in dermal mesenchymal stem cells},
	Ty = {JOUR},
	Url = {https://doi.org/10.1007/s10529-015-1963-5},
	Volume = {38},
	Year = {2016},
	Bdsk-Url-1 = {https://doi.org/10.1007/s10529-015-1963-5}}

@article{Wang:2014aa,
	Abstract = {The concordance of RNA-sequencing (RNA-seq) with microarrays for genome-wide analysis of differential gene expression has not been rigorously assessed using a range of chemical treatment conditions. Here we use a comprehensive study design to generate Illumina RNA-seq and Affymetrix microarray data from the same liver samples of rats exposed in triplicate to varying degrees of perturbation by 27 chemicals representing multiple modes of action (MOAs). The cross-platform concordance in terms of differentially expressed genes (DEGs) or enriched pathways is linearly correlated with treatment effect size (R(2)îŒ†0.8). Furthermore, the concordance is also affected by transcript abundance and biological complexity of the MOA. RNA-seq outperforms microarray (93{\%} versus 75{\%}) in DEG verification as assessed by quantitative PCR, with the gain mainly due to its improved accuracy for low-abundance transcripts. Nonetheless, classifiers to predict MOAs perform similarly when developed using data from either platform. Therefore, the endpoint studied and its biological complexity, transcript abundance and the genomic application are important factors in transcriptomic research and for clinical and regulatory decision making.},
	An = {25150839},
	Author = {Wang, Charles and Gong, Binsheng and Bushel, Pierre R and Thierry-Mieg, Jean and Thierry-Mieg, Danielle and Xu, Joshua and Fang, Hong and Hong, Huixiao and Shen, Jie and Su, Zhenqiang and Meehan, Joe and Li, Xiaojin and Yang, Lu and Li, Haiqing and {\L}abaj, Pawe{\l}P and Kreil, David P and Megherbi, Dalila and Gaj, Stan and Caiment, Florian and van Delft, Joost and Kleinjans, Jos and Scherer, Andreas and Devanarayan, Viswanath and Wang, Jian and Yang, Yong and Qian, Hui-Rong and Lancashire, Lee J and Bessarabova, Marina and Nikolsky, Yuri and Furlanello, Cesare and Chierici, Marco and Albanese, Davide and Jurman, Giuseppe and Riccadonna, Samantha and Filosi, Michele and Visintainer, Roberto and Zhang, Ke K and Li, Jianying and Hsieh, Jui-Hua and Svoboda, Daniel L and Fuscoe, James C and Deng, Youping and Shi, Leming and Paules, Richard S and Auerbach, Scott S and Tong, Weida},
	Date = {2014/09/},
	Date-Added = {2020-06-17 07:21:41 -0700},
	Date-Modified = {2020-06-17 07:21:41 -0700},
	Db = {PubMed},
	Doi = {10.1038/nbt.3001},
	Et = {2014/08/24},
	Isbn = {1546-1696; 1087-0156},
	J2 = {Nat Biotechnol},
	Journal = {Nature biotechnology},
	Keywords = {Animals; *Oligonucleotide Array Sequence Analysis; RNA, Messenger/*genetics; Rats; *Sequence Analysis, RNA},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243706/},
	La = {eng},
	Month = {09},
	Number = {9},
	Pages = {926--932},
	Title = {The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance},
	Ty = {JOUR},
	U1 = {25150839{$[$}pmid{$]$}},
	U2 = {PMC4243706{$[$}pmcid{$]$}},
	U4 = {nbt.3001{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/25150839},
	Volume = {32},
	Year = {2014},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/25150839},
	Bdsk-Url-2 = {https://doi.org/10.1038/nbt.3001}}

@article{Zhao:2014aa,
	Abstract = {To demonstrate the benefits of RNA-Seq over microarray in transcriptome profiling, both RNA-Seq and microarray analyses were performed on RNA samples from a human T cell activation experiment. In contrast to other reports, our analyses focused on the difference, rather than similarity, between RNA-Seq and microarray technologies in transcriptome profiling. A comparison of data sets derived from RNA-Seq and Affymetrix platforms using the same set of samples showed a high correlation between gene expression profiles generated by the two platforms. However, it also demonstrated that RNA-Seq was superior in detecting low abundance transcripts, differentiating biologically critical isoforms, and allowing the identification of genetic variants. RNA-Seq also demonstrated a broader dynamic range than microarray, which allowed for the detection of more differentially expressed genes with higher fold-change. Analysis of the two datasets also showed the benefit derived from avoidance of technical issues inherent to microarray probe performance such as cross-hybridization, non-specific hybridization and limited detection range of individual probes. Because RNA-Seq does not rely on a pre-designed complement sequence detection probe, it is devoid of issues associated with probe redundancy and annotation, which simplified interpretation of the data. Despite the superior benefits of RNA-Seq, microarrays are still the more common choice of researchers when conducting transcriptional profiling experiments. This is likely because RNA-Seq sequencing technology is new to most researchers, more expensive than microarray, data storage is more challenging and analysis is more complex. We expect that once these barriers are overcome, the RNA-Seq platform will become the predominant tool for transcriptome analysis.},
	An = {24454679},
	Author = {Zhao, Shanrong and Fung-Leung, Wai-Ping and Bittner, Anton and Ngo, Karen and Liu, Xuejun},
	Date = {2014/01/16},
	Date-Added = {2020-06-17 07:21:22 -0700},
	Date-Modified = {2020-06-17 07:21:22 -0700},
	Db = {PubMed},
	Doi = {10.1371/journal.pone.0078644},
	Isbn = {1932-6203},
	J2 = {PLoS One},
	Journal = {PloS one},
	Keywords = {Analysis of Variance; Base Sequence; CD4-Positive T-Lymphocytes/*metabolism; Cells, Cultured; *Gene Expression Profiling; Humans; Lymphocyte Activation; Molecular Sequence Annotation; Oligonucleotide Array Sequence Analysis; Protein Isoforms/genetics/metabolism; Sequence Analysis, RNA; *Transcriptome},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894192/},
	La = {eng},
	Month = {01},
	Number = {1},
	Pages = {e78644--e78644},
	Publisher = {Public Library of Science},
	Title = {Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells},
	Ty = {JOUR},
	U1 = {24454679{$[$}pmid{$]$}},
	U2 = {PMC3894192{$[$}pmcid{$]$}},
	U4 = {PONE-D-13-21649{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/24454679},
	Volume = {9},
	Year = {2014},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/24454679},
	Bdsk-Url-2 = {https://doi.org/10.1371/journal.pone.0078644}}

@article{Wilhelm:2009aa,
	Address = {Laboratory of Molecular Genetics of Stem Cells, C.P. 6128 Succursale Centre-Ville, Montr{\'e}al, Que. H3C3J7, Canada. Brian.wilhelm{\char64}umontreal.ca},
	An = {19336255},
	Author = {Wilhelm, Brian T and Landry, Josette-Ren{\'e}e},
	Da = {2009/07//},
	Date-Added = {2020-06-17 07:20:58 -0700},
	Date-Modified = {2020-06-17 07:20:58 -0700},
	Db = {PubMed},
	Doi = {10.1016/j.ymeth.2009.03.016},
	Isbn = {1046-2023},
	J2 = {Methods},
	Journal = {Methods (San Diego, Calif.)},
	La = {eng},
	Number = {3},
	Pages = {249--257},
	Title = {RNA-Seq-quantitative measurement of expression through massively parallel RNA-sequencing},
	Ty = {JOUR},
	Url = {http://europepmc.org/abstract/MED/19336255},
	Url1 = {https://doi.org/10.1016/j.ymeth.2009.03.016},
	Volume = {48},
	Year = {2009},
	Bdsk-Url-1 = {http://europepmc.org/abstract/MED/19336255},
	Bdsk-Url-2 = {https://doi.org/10.1016/j.ymeth.2009.03.016}}

@article{Wang:2009aa,
	Abstract = {RNA-Seq is a recently developed approach to transcriptome profiling that uses deep-sequencing technologies. Studies using this method have already altered our view of the extent and complexity of eukaryotic transcriptomes. RNA-Seq also provides a far more precise measurement of levels of transcripts and their isoforms than other methods. This article describes the RNA-Seq approach, the challenges associated with its application, and the advances made so far in characterizing several eukaryote transcriptomes.},
	An = {19015660},
	Author = {Wang, Zhong and Gerstein, Mark and Snyder, Michael},
	Date = {2009/01/},
	Date-Added = {2020-06-17 07:20:43 -0700},
	Date-Modified = {2020-06-17 07:20:43 -0700},
	Db = {PubMed},
	Doi = {10.1038/nrg2484},
	Isbn = {1471-0064; 1471-0056},
	J2 = {Nat Rev Genet},
	Journal = {Nature reviews. Genetics},
	Keywords = {Animals; Base Sequence; Chromosome Mapping; Exons; Gene Expression Profiling/*methods; Humans; Models, Genetic; Molecular Sequence Data; RNA/*analysis; Sequence Analysis, RNA/*methods; *Transcription, Genetic},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949280/},
	La = {eng},
	Month = {01},
	Number = {1},
	Pages = {57--63},
	Title = {RNA-Seq: a revolutionary tool for transcriptomics},
	Ty = {JOUR},
	U1 = {19015660{$[$}pmid{$]$}},
	U2 = {PMC2949280{$[$}pmcid{$]$}},
	U4 = {nrg2484{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/19015660},
	Volume = {10},
	Year = {2009},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/19015660},
	Bdsk-Url-2 = {https://doi.org/10.1038/nrg2484}}

@article{Kelly:2018aa,
	Abstract = {BACKGROUND: Cancer chemotherapy-associated febrile neutropenia (FN) is a common condition that is deadly when bacteremia is present. Detection of bacteremia depends on culture, which takes days, and no accurate predictive tools applicable to the initial evaluation are available. We utilized metabolomics and transcriptomics to develop multivariable predictors of bacteremia among FN patients. METHODS: We classified emergency department patients with FN and no apparent infection at presentation as bacteremic (cases) or not (controls), according to blood culture results. We assessed relative metabolite abundance in plasma, and relative expression of 2,560 immunology and cancer-related genes in whole blood. We used logistic regression to identify multivariable predictors of bacteremia, and report test characteristics of the derived predictors. RESULTS: For metabolomics, 14 bacteremic cases and 25 non-bacteremic controls were available for analysis; for transcriptomics we had 7 and 22 respectively. A 5-predictor metabolomic model had an area under the receiver operating characteristic curve of 0.991 (95{\%}CI: 0.972,1.000), 100{\%} sensitivity, and 96{\%} specificity for identifying bacteremia. Pregnenolone steroids were more abundant in cases and carnitine metabolites were more abundant in controls. A 3-predictor gene expression model had corresponding results of 0.961 (95{\%}CI: 0.896,1.000), 100{\%}, and 86{\%}. Genes involved in innate immunity were differentially expressed. CONCLUSIONS: Classifiers derived from metabolomic and gene expression data hold promise as objective and accurate predictors of bacteremia among FN patients without apparent infection at presentation, and can provide insights into the underlying biology. Our findings should be considered illustrative, but may lay the groundwork for future biomarker development.},
	An = {29768470},
	Author = {Kelly, Rachel S and Lasky-Su, Jessica and Yeung, Sai-Ching J and Stone, Richard M and Caterino, Jeffrey M and Hagan, Sean C and Lyman, Gary H and Baden, Lindsey R and Glotzbecker, Brett E and Coyne, Christopher J and Baugh, Christopher W and Pallin, Daniel J},
	Date = {2018/05/16},
	Date-Added = {2020-06-16 09:56:48 -0700},
	Date-Modified = {2020-06-16 09:56:48 -0700},
	Db = {PubMed},
	Doi = {10.1371/journal.pone.0197049},
	Isbn = {1932-6203},
	J2 = {PLoS One},
	Journal = {PloS one},
	Keywords = {Adult; *Bacteremia/genetics/immunology/metabolism; *Chemotherapy-Induced Febrile Neutropenia/genetics/immunology/metabolism; Female; Gene Expression Regulation, Neoplastic/*immunology; Humans; Immunity, Innate/genetics; Male; *Metabolome/genetics/immunology; *Metabolomics; Middle Aged; *Neoplasms/drug therapy/genetics/immunology/metabolism},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955575/},
	La = {eng},
	Month = {05},
	Number = {5},
	Pages = {e0197049--e0197049},
	Publisher = {Public Library of Science},
	Title = {Integrative omics to detect bacteremia in patients with febrile neutropenia},
	Ty = {JOUR},
	U1 = {29768470{$[$}pmid{$]$}},
	U2 = {PMC5955575{$[$}pmcid{$]$}},
	U4 = {PONE-D-17-34532{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/29768470},
	Volume = {13},
	Year = {2018},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/29768470},
	Bdsk-Url-2 = {https://doi.org/10.1371/journal.pone.0197049}}

@article{Godoy:2019ab,
	Author = {Godoy, Paula M. and Barczak, Andrea J. and DeHoff, Peter and Srinivasan, Srimeenakshi and Das, Saumya and Erle, David J. and Laurent, Louise C.},
	Date = {2019/01/01},
	Date-Added = {2020-06-16 09:53:41 -0700},
	Date-Modified = {2020-06-16 09:53:41 -0700},
	Doi = {10.1101/645762},
	Journal = {bioRxiv},
	Month = {01},
	N2 = {MicroRNAs (miRNAs) found in biofluids play functional roles in health and in disease pathogenesis, underpinning their potential as clinical biomarkers. Several platforms for measurement of extracellular RNAs have recently become available. We evaluated the reproducibility, accuracy, sensitivity, and specificity of four miRNA quantification platforms, including one widely used discovery approach (small RNA-seq) and three targeted platforms (FirePlex, EdgeSeq, and nCounter). Using pools of synthetic miRNAs, we observed that reproducibility was highest for RNA-seq and EdgeSeq, that all three targeted platforms had lower bias than RNA-seq, and that RNA-seq had the best ability to distinguish between present and absent sequences. Overall reproducibility was lower for plasma samples than synthetic miRNA pools. We compared expression of placental miRNAs in plasma from pregnant and non-pregnant women and observed expected differences with RNA-seq and EdgeSeq, but not FirePlex or nCounter. We conclude that differences in performance among miRNA profiling platforms impact their relative utility as potential assay systems for clinical biomarkers.},
	Pages = {645762},
	Title = {Comparison of miRNA profiling methods using synthetic miRNA pools and standardized exRNA samples reveals substantial performance differences},
	Ty = {JOUR},
	Url = {http://biorxiv.org/content/early/2019/05/24/645762.abstract},
	Year = {2019},
	Bdsk-Url-1 = {http://biorxiv.org/content/early/2019/05/24/645762.abstract},
	Bdsk-Url-2 = {https://doi.org/10.1101/645762}}

@article{Knudsen:2017aa,
	Abstract = {Purpose: Pancreatic ductal adenocarcinoma (PDAC) is associated with an immunosuppressive milieu that supports immune system evasion and disease progression. Here, we interrogated genetic, stromal, and immunologic features of PDAC to delineate impact on prognosis and means to more effectively employ immunotherapy.Experimental Design: A cohort of 109 PDAC cases annotated for overall survival was utilized as a primary discovery cohort. Gene expression analysis defined immunologic subtypes of PDAC that were confirmed in the Cancer Genome Atlas dataset. Stromal and metabolic characteristics of PDAC cases were evaluated by histologic analysis and immunostaining. Enumeration of lymphocytes, as well as staining for CD8, FOXP3, CD68, CD163, PDL1, and CTLA4 characterized immune infiltrate. Neoantigens were determined by analysis of whole-exome sequencing data. Random-forest clustering was employed to define multimarker subtypes, with univariate and multivariate analyses interrogating prognostic significance.Results: PDAC cases exhibited distinct stromal phenotypes that were associated with prognosis, glycolytic and hypoxic biomarkers, and immune infiltrate composition. Immune infiltrate was diverse among PDAC cases and enrichment for M2 macrophages and select immune checkpoints regulators were specifically associated with survival. Composite analysis with neoantigen burden, immunologic, and stromal features defined novel subtypes of PDAC that could have bearing on sensitivity to immunologic therapy approaches. In addition, a subtype with low levels of neoantigens and minimal lymphocyte infiltrate was associated with improved overall survival.Conclusions: The mutational burden of PDAC is associated with distinct immunosuppressive mechanisms that are conditioned by the tumor stromal environment. The defined subtypes have significance for utilizing immunotherapy in the treatment of PDAC. Clin Cancer Res; 23(15); 4429-40. {\copyright}2017 AACR.},
	Address = {McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas.; University of Arizona Cancer Center, University of Arizona, Tucson, Arizona.; Department of Medicine, University of Arizona, Tucson, Arizona.; Department of Medicine, University of Arizona, Tucson, Arizona.; McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas.; McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas.; HTG Molecular Diagnostics, Tucson, Arizona.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.; Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.; David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, New York.; HTG Molecular Diagnostics, Tucson, Arizona.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.; Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, New York.; Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas. awitki@email.arizona.edu.; University of Arizona Cancer Center, University of Arizona, Tucson, Arizona.; Department of Medicine, University of Arizona, Tucson, Arizona.; Department of Pathology, University of Arizona, Tucson, Arizona.},
	Author = {Knudsen, Erik S and Vail, Paris and Balaji, Uthra and Ngo, Hoai and Botros, Ihab W and Makarov, Vladimir and Riaz, Nadeem and Balachandran, Vinod and Leach, Steven and Thompson, Debrah M and Chan, Timothy A and Witkiewicz, Agnieszka K},
	Copyright = {{\copyright}2017 American Association for Cancer Research.},
	Crdt = {2017/03/29 06:00},
	Date = {2017 Aug 1},
	Date-Added = {2020-06-16 09:48:00 -0700},
	Date-Modified = {2020-06-16 09:48:00 -0700},
	Dcom = {20180619},
	Dep = {20170327},
	Doi = {10.1158/1078-0432.CCR-17-0162},
	Edat = {2017/03/30 06:00},
	Gr = {K12 CA184746/CA/NCI NIH HHS/United States; R01 CA127387/CA/NCI NIH HHS/United States; R01 CA211878/CA/NCI NIH HHS/United States},
	Issn = {1078-0432 (Print); 1078-0432 (Linking)},
	Jid = {9502500},
	Journal = {Clin Cancer Res},
	Jt = {Clinical cancer research : an official journal of the American Association for Cancer Research},
	Language = {eng},
	Lid = {10.1158/1078-0432.CCR-17-0162 {$[$}doi{$]$}},
	Lr = {20181113},
	Mh = {Adenocarcinoma/*genetics/immunology/pathology; Antigens, CD/genetics/immunology; Antigens, Differentiation, Myelomonocytic/genetics/immunology; B7-H1 Antigen/genetics/immunology; *Biomarkers; CD8-Positive T-Lymphocytes/immunology/pathology; CTLA-4 Antigen/genetics/immunology; Carcinoma, Pancreatic Ductal/*genetics/immunology/pathology; Female; Gene Expression Regulation, Neoplastic/genetics/immunology; Humans; Male; Middle Aged; Mutation; *Prognosis; Receptors, Cell Surface/genetics/immunology; Stromal Cells/immunology/pathology; Whole Exome Sequencing},
	Mhda = {2018/06/20 06:00},
	Mid = {NIHMS862034},
	Month = {Aug},
	Number = {15},
	Own = {NLM},
	Pages = {4429--4440},
	Phst = {2017/01/18 00:00 {$[$}received{$]$}; 2017/02/23 00:00 {$[$}revised{$]$}; 2017/03/14 00:00 {$[$}accepted{$]$}; 2017/03/30 06:00 {$[$}pubmed{$]$}; 2018/06/20 06:00 {$[$}medline{$]$}; 2017/03/29 06:00 {$[$}entrez{$]$}},
	Pii = {1078-0432.CCR-17-0162},
	Pmc = {PMC5951386},
	Pmid = {28348045},
	Pst = {ppublish},
	Pt = {Journal Article},
	Rn = {0 (Antigens, CD); 0 (Antigens, Differentiation, Myelomonocytic); 0 (B7-H1 Antigen); 0 (Biomarkers); 0 (CD163 antigen); 0 (CD274 protein, human); 0 (CTLA-4 Antigen); 0 (CTLA4 protein, human); 0 (Receptors, Cell Surface)},
	Sb = {IM},
	Status = {MEDLINE},
	Title = {Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.},
	Volume = {23},
	Year = {2017},
	Bdsk-Url-1 = {https://doi.org/10.1158/1078-0432.CCR-17-0162}}

@article{Takahashi:2019aa,
	Abstract = {BACKGROUND: Sinonasal undifferentiated carcinoma (SNUC) is a rare, highly aggressive cancer. It is often difficult to determine whether SNUC is a distinct pathologic entity with poorly differentiated neuroendocrine features or it represents an undifferentiated tumor of squamous lineage. Also, reliable histopathologic markers that distinguish SNUC from poorly differentiated sinonasal squamous cell carcinoma (SNSCC) are lacking. Therefore, identification of new diagnostic molecular markers for SNUC is needed. METHODS: Treatment-na{\"\i}ve tumor specimens obtained from 15 SNUC and 6 SNSCC patients were used. Gene expression analysis was performed using an oncology panel. RESULTS: An unsupervised cluster analysis divided the patients into the one with only SNUCs and the one with mainly SNSCCs. Of 132 differentially expressed genes, 7 genes completely distinguished SNUCs from SNSCCs. SNUCs were enriched in sets of genes related to DNA repair, synthesis/replication, and cell division. CONCLUSIONS: Our study identified new diagnostic markers and potential therapeutic targets for SNUC.},
	Address = {Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt.; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.},
	Auid = {ORCID: 0000-0003-2390-1998; ORCID: 0000-0002-3531-8241},
	Author = {Takahashi, Yoko and Gleber-Netto, Frederico O and Bell, Diana and Roberts, Dianna and Xie, Tong-Xin and Abdelmeguid, Ahmed S and Pickering, Curtis and Myers, Jeffrey N and Hanna, Ehab Y},
	Copyright = {{\copyright}2019 Wiley Periodicals, Inc.},
	Crdt = {2019/04/02 06:00},
	Date = {2019 Aug},
	Date-Added = {2020-06-16 09:38:01 -0700},
	Date-Modified = {2020-06-16 09:38:01 -0700},
	Dep = {20190401},
	Doi = {10.1002/hed.25748},
	Edat = {2019/04/02 06:00},
	Gr = {University of Texas MD Anderson Cancer Center/International; Various Sinus Cancer Research Fund/International},
	Issn = {1097-0347 (Electronic); 1043-3074 (Linking)},
	Jid = {8902541},
	Journal = {Head Neck},
	Jt = {Head \& neck},
	Keywords = {*comprehensive gene expression study; *diagnostic markers; *sinonasal squamous cell carcinoma; *sinonasal undifferentiated carcinoma; *therapeutic targets},
	Language = {eng},
	Lid = {10.1002/hed.25748 {$[$}doi{$]$}},
	Lr = {20200226},
	Mhda = {2019/04/02 06:00},
	Month = {Aug},
	Number = {8},
	Oto = {NOTNLM},
	Own = {NLM},
	Pages = {2688--2695},
	Phst = {2018/12/01 00:00 {$[$}received{$]$}; 2019/01/24 00:00 {$[$}revised{$]$}; 2019/03/11 00:00 {$[$}accepted{$]$}; 2019/04/02 06:00 {$[$}pubmed{$]$}; 2019/04/02 06:00 {$[$}medline{$]$}; 2019/04/02 06:00 {$[$}entrez{$]$}},
	Pl = {United States},
	Pmid = {30932264},
	Pst = {ppublish},
	Pt = {Journal Article; Research Support, Non-U.S. Gov't},
	Sb = {IM},
	Status = {In-Process},
	Title = {Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma.},
	Volume = {41},
	Year = {2019},
	Bdsk-Url-1 = {https://doi.org/10.1002/hed.25748}}

@article{Songia:2018aa,
	Annote = {doi: 10.1080/15476286.2018.1526538},
	Author = {Songia, Paola and Chiesa, Mattia and Valerio, Vincenza and Moschetta, Donato and Myasoedova, Veronika A. and D'Alessandra, Yuri and Poggio, Paolo},
	Booktitle = {RNA Biology},
	Da = {2018/10/03},
	Date = {2018/10/03},
	Date-Added = {2020-06-16 09:19:41 -0700},
	Date-Modified = {2020-06-16 09:19:41 -0700},
	Doi = {10.1080/15476286.2018.1526538},
	Isbn = {1547-6286},
	Journal = {RNA Biology},
	Journal1 = {RNA Biology},
	M3 = {doi: 10.1080/15476286.2018.1526538},
	Month = {10},
	Number = {10},
	Pages = {1268--1272},
	Publisher = {Taylor \& Francis},
	Title = {Direct screening of plasma circulating microRNAs},
	Ty = {JOUR},
	Url = {https://doi.org/10.1080/15476286.2018.1526538},
	Volume = {15},
	Year = {2018},
	Year1 = {2018},
	Bdsk-Url-1 = {https://doi.org/10.1080/15476286.2018.1526538}}

@article{Qi:2019aa,
	Abstract = {Clinical biomarker studies are often hindered by the scarcity or suboptimal quality of biological specimens. EdgeSeq, a transcriptomics analysis platform, combines quantitative nuclease protection assay technology with next-generation sequencing, using small amounts of starting material and delivering reproducible gene expression profiles from challenging material, such as formalin-fixed, paraffin-embedded (FFPE) tissue. To evaluate EdgeSeq for analysis of archives of stained FFPE tissue, EdgeSeq was performed on unstained, hematoxylin and eosin (H&E)-stained, and immunohistochemistry-stained slides from patients with small-cell and non-small-cell lung cancer. Pairwise comparisons of gene expression profiles from stained and unstained slides showed higher Pearson correlation coefficients with H&E staining (0.86 to 0.97) than with immunohistochemistry staining (0.21 to 0.56). A 25-gene interferon-Î³ signature score from unstained slides showed a Pearson correlation coefficient of 0.92 with H&E-stained slides and a significant Spearman correlation (P = 0.0025) with immune scores. To test gene expression profiling in small samples, FFPE sample equivalents were examined from 5.0 to 0.08 mm(2) of a section (5 Î¼m thick); sample equivalents â‰¥0.31 mm(2) showed alignment rates >69% and pairwise Pearson correlation coefficients â‰¥0.87. EdgeSeq can, thus, be used to profile small and H&E-stained FFPE tumor specimens to obtain biomarker data from limited tissue in oncology clinical trials and enable research into tumor microenvironment and immune cell engagement with tumors at the locoregional level.},
	Address = {Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey. Electronic address: lisu.wang@bms.com.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.; Pharmaceutical Services \& Companion Diagnostics, HTG Molecular Diagnostics, Inc., Tucson, Arizona.; Pharmaceutical Services \& Companion Diagnostics, HTG Molecular Diagnostics, Inc., Tucson, Arizona.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.; Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey.},
	Author = {Qi, Zhenhao and Wang, Lisu and Desai, Keyur and Cogswell, John and Stern, Mark and Lawson, Byron and Kerkar, Sid P and Vitazka, Patrik},
	Copyright = {Copyright {\copyright}2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.},
	Crdt = {2019/07/01 06:00},
	Date = {2019 Sep},
	Date-Added = {2020-06-16 08:12:03 -0700},
	Date-Modified = {2020-06-16 08:12:03 -0700},
	Dep = {20190627},
	Doi = {10.1016/j.jmoldx.2019.04.011},
	Edat = {2019/07/01 06:00},
	Issn = {1943-7811 (Electronic); 1525-1578 (Linking)},
	Jid = {100893612},
	Journal = {J Mol Diagn},
	Jt = {The Journal of molecular diagnostics : JMD},
	Language = {eng},
	Lid = {S1525-1578(18)30380-5 {$[$}pii{$]$}; 10.1016/j.jmoldx.2019.04.011 {$[$}doi{$]$}},
	Lr = {20200226},
	Mhda = {2019/07/01 06:00},
	Month = {Sep},
	Number = {5},
	Own = {NLM},
	Pages = {796--807},
	Phst = {2018/09/14 00:00 {$[$}received{$]$}; 2019/03/06 00:00 {$[$}revised{$]$}; 2019/04/16 00:00 {$[$}accepted{$]$}; 2019/07/01 06:00 {$[$}pubmed{$]$}; 2019/07/01 06:00 {$[$}medline{$]$}; 2019/07/01 06:00 {$[$}entrez{$]$}},
	Pii = {S1525-1578(18)30380-5},
	Pl = {United States},
	Pmid = {31255795},
	Pst = {ppublish},
	Pt = {Journal Article; Research Support, Non-U.S. Gov't},
	Sb = {IM},
	Status = {In-Process},
	Title = {Reliable Gene Expression Profiling from Small and Hematoxylin and Eosin-Stained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform.},
	Volume = {21},
	Year = {2019},
	Bdsk-Url-1 = {https://doi.org/10.1016/j.jmoldx.2019.04.011}}

@article{Qi:2016aa,
	Abstract = {AIM: Formalin-fixed, paraffin-embedded (FFPE) clinical tissue samples have the potential to provide valuable gene-expression data for the development of cancer biomarkers. However, FFPE RNA is extensively fragmented, presenting a significant challenge for reliably detecting gene expression using traditional qPCR methods. RESULTS: We evaluated three novel methodologies along with the traditional qPCR method for their ability to detect Notch pathway gene expression in colorectal cancer FFPE tissue RNAs. We found that quantitative nuclease protection assay-detected gene expression in high-quality RNAs as sensitively as qPCR, and consistently detected mRNAs in highly fragmented FFPE tissue RNAs. CONCLUSION: Quantitative nuclease protection assay represents an improved methodology for detecting gene expression in FFPE tissue and has the potential to advance the development of cancer biomarkers.},
	Address = {Clinical Translational Technologies \& Operations, Bristol-Myers Squibb, Route 206 \& Province Line Road, Princeton, NJ 08543, USA.; Clinical Translational Technologies \& Operations, Bristol-Myers Squibb, Route 206 \& Province Line Road, Princeton, NJ 08543, USA.; Genetically Defined Diseases \& Genomics, Bristol-Myers Squibb, Route 206 \& Province Line Road, Princeton, NJ 08543, USA.; Genetically Defined Diseases \& Genomics, Bristol-Myers Squibb, Route 206 \& Province Line Road, Princeton, NJ 08543, USA.; Clinical Translational Technologies \& Operations, Bristol-Myers Squibb, Route 206 \& Province Line Road, Princeton, NJ 08543, USA.},
	Author = {Qi, Zhenhao and Wang, Lisu and He, Aiqing and Ma-Edmonds, Manling and Cogswell, John},
	Crdt = {2016/10/08 06:00},
	Date = {2016 Nov},
	Date-Added = {2020-06-16 08:06:27 -0700},
	Date-Modified = {2020-06-16 08:06:27 -0700},
	Dep = {20161007},
	Doi = {10.4155/bio-2016-0186},
	Edat = {2016/10/08 06:00},
	Issn = {1757-6199 (Electronic); 1757-6180 (Linking)},
	Jid = {101512484},
	Journal = {Bioanalysis},
	Jt = {Bioanalysis},
	Keywords = {FFPE tissue; Notch pathway; RNA; biomarkers; colorectal cancer; gene expression; qPCR; quantitative nuclease protection assay},
	Language = {eng},
	Lid = {10.4155/bio-2016-0186 {$[$}doi{$]$}},
	Lr = {20191120},
	Mhda = {2016/10/08 06:01},
	Month = {Nov},
	Number = {22},
	Oto = {NOTNLM},
	Own = {NLM},
	Pages = {2305--2316},
	Phst = {2016/10/08 06:00 {$[$}pubmed{$]$}; 2016/10/08 06:01 {$[$}medline{$]$}; 2016/10/08 06:00 {$[$}entrez{$]$}},
	Pl = {England},
	Pmid = {27712086},
	Pst = {ppublish},
	Pt = {Journal Article},
	Status = {PubMed-not-MEDLINE},
	Title = {Evaluation and selection of a non-PCR based technology for improved gene expression profiling from clinical formalin-fixed, paraffin-embedded samples.},
	Volume = {8},
	Year = {2016},
	Bdsk-Url-1 = {https://doi.org/10.4155/bio-2016-0186}}

@article{Suda:2017aa,
	Abstract = {INTRODUCTION: Expression of immune markers is of scientific interest because of their potential roles as predictive biomarkers for immunotherapy. Although the microenvironment of metastatic tumors and/or therapy-inducible histological transformation may affect the expression of these immune markers, there are few data regarding this context. METHODS: A 76-year-old never-smoking female with EGFR-mutated lung adenocarcinoma (AC) acquired resistance to gefitinib. After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel. RESULTS: Programmed death ligand 1 (PD-L1) protein was partially expressed in tumor cells with AC lesions (T790M) but not in tumor cells with SCLC transformation. The liver metastasis with SCLC transformation showed no stromal PD-L1 expression and scant tumor-infiltrating lymphocytes, whereas the other lesions demonstrated stromal PD-L1 staining and infiltration of CD8-positive T cells. Data generated using an immuno-oncology gene expression panel indicated a higher level of T-cell costimulatory molecules and lower expression of type I interferon-regulated genes in lesions with SCLC transformation. CONCLUSION: These data highlight the heterogeneity of expression of immune markers depending on the metastatic sites and histological transformation and indicate that the biopsy specimen from one lesion may not be representative of immune marker status for all lesions.},
	Address = {Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Division of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.; Department of Respiratory Medicine, Higashi-Hiroshima Medical Center, Higashi-Hiroshima, Japan.; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.; Division of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.; Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Electronic address: fred.hirsch@ucdenver.edu.},
	Author = {Suda, Kenichi and Murakami, Isao and Yu, Hui and Kim, Jihye and Ellison, Kim and Rivard, Christopher J and Mitsudomi, Tetsuya and Hirsch, Fred R},
	Copyright = {Copyright {\copyright}2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.},
	Crdt = {2017/02/15 06:00},
	Date = {2017 Jun},
	Date-Added = {2020-06-16 07:36:42 -0700},
	Date-Modified = {2020-06-16 07:36:42 -0700},
	Dcom = {20180314},
	Dep = {20170211},
	Doi = {10.1016/j.jtho.2017.02.002},
	Edat = {2017/02/15 06:00},
	Issn = {1556-1380 (Electronic); 1556-0864 (Linking)},
	Jid = {101274235},
	Journal = {J Thorac Oncol},
	Jt = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
	Keywords = {*Acquired resistance; *Autopsy; *EGFR mutation; *Gefitinib; *Immune biomarkers; *PD-L1},
	Language = {eng},
	Lid = {S1556-0864(17)30098-9 {$[$}pii{$]$}; 10.1016/j.jtho.2017.02.002 {$[$}doi{$]$}},
	Lr = {20181202},
	Mh = {Adenocarcinoma/drug therapy/metabolism/secondary; Aged; Biomarkers/*metabolism; Cell Transformation, Neoplastic/drug effects/metabolism/pathology; *Drug Resistance, Neoplasm; ErbB Receptors/*antagonists \& inhibitors/genetics; Female; Gefitinib; Humans; Liver Neoplasms/drug therapy/metabolism/secondary; Lung Neoplasms/drug therapy/*metabolism/pathology; Lymphatic Metastasis; Mutation; Prognosis; Protein Kinase Inhibitors/pharmacology; Quinazolines/*pharmacology; Small Cell Lung Carcinoma/drug therapy/*metabolism/pathology},
	Mhda = {2018/03/15 06:00},
	Month = {Jun},
	Number = {6},
	Oto = {NOTNLM},
	Own = {NLM},
	Pages = {1015--1020},
	Phst = {2017/01/03 00:00 {$[$}received{$]$}; 2017/02/01 00:00 {$[$}revised{$]$}; 2017/02/03 00:00 {$[$}accepted{$]$}; 2017/02/15 06:00 {$[$}pubmed{$]$}; 2018/03/15 06:00 {$[$}medline{$]$}; 2017/02/15 06:00 {$[$}entrez{$]$}},
	Pii = {S1556-0864(17)30098-9},
	Pl = {United States},
	Pmid = {28193529},
	Pst = {ppublish},
	Pt = {Case Reports; Journal Article},
	Rn = {0 (Biomarkers); 0 (Protein Kinase Inhibitors); 0 (Quinazolines); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (ErbB Receptors); S65743JHBS (Gefitinib)},
	Sb = {IM},
	Status = {MEDLINE},
	Title = {Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.},
	Volume = {12},
	Year = {2017},
	Bdsk-Url-1 = {https://doi.org/10.1016/j.jtho.2017.02.002}}

@article{Girard:2016aa,
	Abstract = {PURPOSE: Most non-small cell lung cancers (NSCLC) are now diagnosed from small specimens, and classification using standard pathology methods can be difficult. This is of clinical relevance as many therapy regimens and clinical trials are histology dependent. The purpose of this study was to develop an mRNA expression signature as an adjunct test for routine histopathologic classification of NSCLCs. EXPERIMENTAL DESIGN: A microarray dataset of resected adenocarcinomas (ADC) and squamous cell carcinomas (SCC) was used as the learning set for an ADC-SCC signature. The Cancer Genome Atlas (TCGA) lung RNAseq dataset was used for validation. Another microarray dataset of ADCs and matched nonmalignant lung was used as the learning set for a tumor versus nonmalignant signature. The classifiers were selected as the most differentially expressed genes and sample classification was determined by a nearest distance approach. RESULTS: We developed a 62-gene expression signature that contained many genes used in immunostains for NSCLC typing. It includes 42 genes that distinguish ADC from SCC and 20 genes differentiating nonmalignant lung from lung cancer. Testing of the TCGA and other public datasets resulted in high prediction accuracies (93%-95%). In addition, a prediction score was derived that correlates both with histologic grading and prognosis. We developed a practical version of the Classifier using the HTG EdgeSeq nuclease protection-based technology in combination with next-generation sequencing that can be applied to formalin-fixed paraffin-embedded (FFPE) tissues and small biopsies. CONCLUSIONS: Our RNA classifier provides an objective, quantitative method to aid in the pathologic diagnosis of lung cancer. Clin Cancer Res; 22(19); 4880-9. {\copyright}2016 AACR.},
	Address = {Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas. Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.; HTG Molecular Diagnostics, Tucson, Arizona.; HTG Molecular Diagnostics, Tucson, Arizona.; Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, Texas.; Department of Clinical Science, University of Texas Southwestern Medical Center, Dallas, Texas. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.; Department of Thoracic Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Thoracic Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas. Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.; Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, Texas. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. Adi.Gazdar@UTsouthwestern.edu.},
	Author = {Girard, Luc and Rodriguez-Canales, Jaime and Behrens, Carmen and Thompson, Debrah M and Botros, Ihab W and Tang, Hao and Xie, Yang and Rekhtman, Natasha and Travis, William D and Wistuba, Ignacio I and Minna, John D and Gazdar, Adi F},
	Cois = {Disclosure of Potential Conflicts of Interest: Ihab Botros and Debrah Thompson are both employees and stockholders of HTG Molecular Diagnostics, Inc. (HTG). Ignacio Wistuba is a consultant for HTG and an occasional participant of its advisory board. He also received financial support from HTG as part of a research agreement. No other authors of this article have financial ties to HTG.},
	Copyright = {{\copyright}2016 American Association for Cancer Research.},
	Crdt = {2016/06/30 06:00},
	Date = {2016 Oct 1},
	Date-Added = {2020-06-15 07:29:00 -0700},
	Date-Modified = {2020-06-15 07:29:00 -0700},
	Dcom = {20180105},
	Dep = {20160628},
	Doi = {10.1158/1078-0432.CCR-15-2900},
	Edat = {2016/06/30 06:00},
	Gr = {P30 CA016672/CA/NCI NIH HHS/United States; P50 CA070907/CA/NCI NIH HHS/United States; R44 HG005949/HG/NHGRI NIH HHS/United States; U01 CA086402/CA/NCI NIH HHS/United States},
	Issn = {1078-0432 (Print); 1078-0432 (Linking)},
	Jid = {9502500},
	Journal = {Clin Cancer Res},
	Jt = {Clinical cancer research : an official journal of the American Association for Cancer Research},
	Language = {eng},
	Lr = {20181113},
	Mh = {Biomarkers, Tumor/genetics; Carcinoma, Non-Small-Cell Lung/*classification/genetics/pathology; Gene Expression Profiling/*methods; Humans; Lung Neoplasms/*classification/genetics/pathology; RNA, Messenger/analysis; SEER Program; Transcriptome},
	Mhda = {2018/01/06 06:00},
	Mid = {NIHMS800338},
	Month = {Oct},
	Number = {19},
	Own = {NLM},
	Pages = {4880--4889},
	Phst = {2015/12/01 00:00 {$[$}received{$]$}; 2016/06/12 00:00 {$[$}accepted{$]$}; 2016/06/30 06:00 {$[$}pubmed{$]$}; 2018/01/06 06:00 {$[$}medline{$]$}; 2016/06/30 06:00 {$[$}entrez{$]$}},
	Pii = {1078-0432.CCR-15-2900},
	Pmc = {PMC5492382},
	Pmid = {27354471},
	Pst = {ppublish},
	Pt = {Journal Article},
	Rn = {0 (Biomarkers, Tumor); 0 (RNA, Messenger)},
	Sb = {IM},
	Status = {MEDLINE},
	Title = {An Expression Signature as an Aid to the Histologic Classification of Non-Small Cell Lung Cancer.},
	Volume = {22},
	Year = {2016},
	Bdsk-Url-1 = {https://doi.org/10.1158/1078-0432.CCR-15-2900}}

@article{Lizarraga:2016aa,
	Abstract = {AIM: Differences in children's development and susceptibility to diseases and exposures have been observed by sex, yet human studies of sex differences in miRNAs are limited. MATERIALS \& METHODS: The genome-wide miRNA expression was characterized by sequencing-based EdgeSeq assay in cord blood buffy coats from 89 newborns, and 564 miRNAs were further analyzed. RESULTS: Differential expression of most miRNAs was higher in boys. Neurodevelopment, RNA metabolism and metabolic ontology terms were enriched among miRNA targets. The majority of upregulated miRNAs (86{\%}) validated by nCounter maintained positive-fold change values; however, only 21{\%} reached statistical significance by false discovery rate. CONCLUSION: Accounting for host factors like sex may improve the sensitivity of epigenetic analyses for epidemiological studies in early childhood.},
	An = {27882772},
	Author = {Lizarraga, Daneida and Huen, Karen and Combs, Mary and Escudero-Fung, Maria and Eskenazi, Brenda and Holland, Nina},
	Date = {2016/12/},
	Date-Added = {2020-06-15 06:52:06 -0700},
	Date-Modified = {2020-06-15 06:52:06 -0700},
	Db = {PubMed},
	Doi = {10.2217/epi-2016-0031},
	Et = {2016/11/24},
	Isbn = {1750-192X; 1750-1911},
	J2 = {Epigenomics},
	Journal = {Epigenomics},
	Keywords = {*cord blood; *early life; *epigenetics; *filtering; *miRNA; *miRNAome; *newborns; *next-generation sequencing; *normalization procedures; *sex differences; Blood Buffy Coat/metabolism; Female; Fetal Blood/metabolism; Humans; Infant, Newborn; Male; MicroRNAs/*genetics; Sequence Analysis, RNA; Sex Factors},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289041/},
	La = {eng},
	Month = {12},
	Number = {12},
	Pages = {1619--1635},
	Publisher = {Future Medicine Ltd.},
	Title = {miRNAs differentially expressed by next-generation sequencing in cord blood buffy coat samples of boys and girls},
	Ty = {JOUR},
	U1 = {27882772{$[$}pmid{$]$}},
	U2 = {PMC5289041{$[$}pmcid{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/27882772},
	Volume = {8},
	Year = {2016},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/27882772},
	Bdsk-Url-2 = {https://doi.org/10.2217/epi-2016-0031}}

@article{Holik:2017aa,
	Abstract = {Carefully designed control experiments provide a gold standard for benchmarking different genomics research tools. A shortcoming of many gene expression control studies is that replication involves profiling the same reference RNA sample multiple times. This leads to low, pure technical noise that is atypical of regular studies. To achieve a more realistic noise structure, we generated a RNA-sequencing mixture experiment using two cell lines of the same cancer type. Variability was added by extracting RNA from independent cell cultures and degrading particular samples. The systematic gene expression changes induced by this design allowed benchmarking of different library preparation kits (standard poly-A versus total RNA with Ribozero depletion) and analysis pipelines. Data generated using the total RNA kit had more signal for introns and various RNA classes (ncRNA, snRNA, snoRNA) and less variability after degradation. For differential expression analysis, voom with quality weights marginally outperformed other popular methods, while for differential splicing, DEXSeq was simultaneously the most sensitive and the most inconsistent method. For sample deconvolution analysis, DeMix outperformed IsoPure convincingly. Our RNA-sequencing data set provides a valuable resource for benchmarking different protocols and data pre-processing workflows. The extra noise mimics routine lab experiments more closely, ensuring any conclusions are widely applicable.},
	An = {PMC5389713},
	Author = {Holik, Aliaksei Z and Law, Charity W and Liu, Ruijie and Wang, Zeya and Wang, Wenyi and Ahn, Jaeil and Asselin-Labat, Marie-Liesse and Smyth, Gordon K and Ritchie, Matthew E},
	Date = {2017},
	Date-Added = {2020-06-06 08:56:45 -0700},
	Date-Modified = {2020-06-06 08:56:45 -0700},
	Db = {PMC},
	Doi = {10.1093/nar/gkw1063},
	Isbn = {0305-1048; 1362-4962},
	J1 = {Nucleic Acids Res},
	Journal = {Nucleic Acids Research},
	Month = {03},
	Number = {5},
	Pages = {e30--e30},
	Publisher = {Oxford University Press},
	Title = {RNA-seq mixology: designing realistic control experiments to compare protocols and analysis methods},
	Ty = {JOUR},
	U1 = {gkw1063{$[$}PII{$]$}; 27899618{$[$}pmid{$]$}},
	Url = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389713/},
	Volume = {45},
	Year = {2017},
	Year1 = {2016/11/28},
	Year2 = {2016/10/24/accepted},
	Year3 = {2016/10/18/revised},
	Year4 = {2016/07/18/received},
	Bdsk-Url-1 = {http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389713/},
	Bdsk-Url-2 = {https://doi.org/10.1093/nar/gkw1063}}

@article{Shippy:2006aa,
	Abstract = {We have assessed the utility of RNA titration samples for evaluating microarray platform performance and the impact of different normalization methods on the results obtained. As part of the MicroArray Quality Control project, we investigated the performance of five commercial microarray platforms using two independent RNA samples and two titration mixtures of these samples. Focusing on 12,091 genes common across all platforms, we determined the ability of each platform to detect the correct titration response across the samples. Global deviations from the response predicted by the titration ratios were observed. These differences could be explained by variations in relative amounts of messenger RNA as a fraction of total RNA between the two independent samples. Overall, both the qualitative and quantitative correspondence across platforms was high. In summary, titration samples may be regarded as a valuable tool, not only for assessing microarray platform performance and different analysis methods, but also for determining some underlying biological features of the samples.},
	An = {16964226},
	Author = {Shippy, Richard and Fulmer-Smentek, Stephanie and Jensen, Roderick V and Jones, Wendell D and Wolber, Paul K and Johnson, Charles D and Pine, P Scott and Boysen, Cecilie and Guo, Xu and Chudin, Eugene and Sun, Yongming Andrew and Willey, James C and Thierry-Mieg, Jean and Thierry-Mieg, Danielle and Setterquist, Robert A and Wilson, Mike and Lucas, Anne Bergstrom and Novoradovskaya, Natalia and Papallo, Adam and Turpaz, Yaron and Baker, Shawn C and Warrington, Janet A and Shi, Leming and Herman, Damir},
	Date = {2006},
	Date-Added = {2020-06-06 08:47:08 -0700},
	Date-Modified = {2020-06-06 08:47:08 -0700},
	Db = {PubMed},
	Doi = {10.1038/nbt1241},
	Isbn = {1087-0156; 1546-1696},
	J2 = {Nat Biotechnol},
	Journal = {Nature biotechnology},
	Keywords = {Algorithms; Equipment Failure Analysis/*methods; Gene Expression Profiling/*instrumentation/*standards; Oligonucleotide Array Sequence Analysis/*instrumentation/*standards; RNA/*analysis/*genetics; Reference Values; Reproducibility of Results; Sensitivity and Specificity; United States},
	L2 = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3272080/},
	La = {eng},
	Month = {09},
	Number = {9},
	Pages = {1123--1131},
	Title = {Using RNA sample titrations to assess microarray platform performance and normalization techniques},
	Ty = {JOUR},
	U1 = {16964226{$[$}pmid{$]$}},
	U2 = {PMC3272080{$[$}pmcid{$]$}},
	U4 = {nbt1241{$[$}PII{$]$}},
	Url = {https://pubmed.ncbi.nlm.nih.gov/16964226},
	Volume = {24},
	Year = {2006},
	Bdsk-Url-1 = {https://pubmed.ncbi.nlm.nih.gov/16964226},
	Bdsk-Url-2 = {https://doi.org/10.1038/nbt1241}}

@article{Mestdagh:2014aa,
	Author = {Mestdagh, Pieter and Hartmann, Nicole and Baeriswyl, Lukas and Andreasen, Ditte and Bernard, Nathalie and Chen, Caifu and Cheo, David and D'Andrade, Petula and DeMayo, Mike and Dennis, Lucas and Derveaux, Stefaan and Feng, Yun and Fulmer-Smentek, Stephanie and Gerstmayer, Bernhard and Gouffon, Julia and Grimley, Chris and Lader, Eric and Lee, Kathy and Luo, Shujun and Vandesompele, Jo},
	Date = {2014/06/29},
	Date-Added = {2020-06-06 08:44:14 -0700},
	Date-Modified = {2020-06-06 08:44:14 -0700},
	Doi = {10.1038/nMeth.3014},
	Month = {06},
	Title = {Evaluation of quantitative miRNA expression platforms in the microRNA quality control (MIRQC) study},
	Ty = {JOUR},
	Year = {2014},
	Bdsk-Url-1 = {https://doi.org/10.1038/nMeth.3014}}

@article{Aissaoui:2017aa,
	Author = {Salim Aissaoui and Bonnie LaFleur},
	Date-Added = {2020-06-06 08:42:43 -0700},
	Date-Modified = {2020-06-06 08:43:57 -0700},
	Journal = {ESHG},
	Title = {HTG EdgeSeq miRNA Whole Transcriptome Assay Platform Performance Metrics Utilizing the MicroRNA (miRQC) Study Specimens},
	Year = {2017}}

@article{Pine:2018aa,
	Abstract = {The potential utility of microRNA as biomarkers for early detection of cancer and other diseases is being investigated with genome-scale profiling of differentially expressed microRNA. Processes for measurement assurance are critical components of genome-scale measurements. Here, we evaluated the utility of a set of total RNA samples, designed with between-sample differences in the relative abundance of miRNAs, as process controls.},
	Author = {Pine, P. Scott and Lund, Steven P. and Parsons, Jerod R. and Vang, Lindsay K. and Mahabal, Ashish A. and Cinquini, Luca and Kelly, Sean C. and Kincaid, Heather and Crichton, Daniel J. and Spira, Avrum and Liu, Gang and Gower, Adam C. and Pass, Harvey I. and Goparaju, Chandra and Dubinett, Steven M. and Krysan, Kostyantyn and Stass, Sanford A. and Kukuruga, Debra and Van Keuren-Jensen, Kendall and Courtright-Lim, Amanda and Thompson, Karol L. and Rosenzweig, Barry A. and Sorbara, Lynn and Srivastava, Sudhir and Salit, Marc L.},
	Da = {2018/03/06},
	Date-Added = {2020-06-05 12:35:16 -0700},
	Date-Modified = {2020-06-05 12:35:16 -0700},
	Doi = {10.1186/s12864-018-4496-1},
	Id = {Pine2018},
	Isbn = {1471-2164},
	Journal = {BMC Genomics},
	Number = {1},
	Pages = {180},
	Title = {Summarizing performance for genome scale measurement of miRNA: reference samples and metrics},
	Ty = {JOUR},
	Url = {https://doi.org/10.1186/s12864-018-4496-1},
	Volume = {19},
	Year = {2018},
	Bdsk-Url-1 = {https://doi.org/10.1186/s12864-018-4496-1}}

@article{Das:2019aa,
	Abstract = {The Extracellular RNA Communication Consortium (ERCC) was launched to accelerate progress in the new field of extracellular RNA (exRNA) biology and to establish whether exRNAs and their carriers, including extracellular vesicles (EVs), can mediate intercellular communication and be utilized for clinical applications. Phase 1 of the ERCC focused on exRNA/EV biogenesis and function, discovery of exRNA biomarkers, development of exRNA/EV-based therapeutics, and construction of a robust set of reference exRNA profiles for a variety of biofluids. Here, we present progress by ERCC investigators in these areas, and we discuss collaborative projects directed at development of robust methods for EV/exRNA isolation and analysis and tools for sharing and computational analysis of exRNA profiling data.},
	Author = {Das, Saumya and Abdel-Mageed, Asim B. and Adamidi, Catherine and Adelson, P. David and Akat, Kemal M. and Alsop, Eric and Ansel, K. Mark and Arango, Jorge and Aronin, Neil and Avsaroglu, Seda Kilinc and Azizian, Azadeh and Balaj, Leonora and Ben-Dov, Iddo Z. and Bertram, Karl and Bitzer, Markus and Blelloch, Robert and Bogardus, Kimberly A. and Breakefield, Xandra Owens and Calin, George A. and Carter, Bob S. and Charest, Al and Chen, Clark C. and Chitnis, Tanuja and Coffey, Robert J. and Courtright-Lim, Amanda and Datta, Amrita and DeHoff, Peter and Diacovo, Thomas G. and Erle, David J. and Etheridge, Alton and Ferrer, Marc and Franklin, Jeffrey L. and Freedman, Jane E. and Galas, David J. and Galeev, Timur and Gandhi, Roopali and Garcia, Aitor and Gerstein, Mark Bender and Ghai, Vikas and Ghiran, Ionita Calin and Giraldez, Maria D. and Goga, Andrei and Gogakos, Tasos and Goilav, Beatrice and Gould, Stephen J. and Guo, Peixuan and Gupta, Mihir and Hochberg, Fred and Huang, Bo and Huentelman, Matt and Hunter, Craig and Hutchins, Elizabeth and Jackson, Andrew R. and Kalani, M. Yashar S. and Kanlikilicer, Pinar and Karaszti, Reka Agnes and Van Keuren-Jensen, Kendall and Khvorova, Anastasia and Kim, Yong and Kim, Hogyoung and Kim, Taek Kyun and Kitchen, Robert and Kraig, Richard P. and Krichevsky, Anna M. and Kwong, Raymond Y. and Laurent, Louise C. and Lee, Minyoung and L'Etoile, Noelle and Levy, Shawn E. and Li, Feng and Li, Jenny and Li, Xin and Lopez-Berestein, Gabriel and Lucero, Rocco and Mateescu, Bogdan and Matin, A. C. and Max, Klaas E. A. and McManus, Michael T. and Mempel, Thorsten R. and Meyer, Cindy and Milosavljevic, Aleksandar and Mondal, Debasis and Mukamal, Kenneth Jay and Murillo, Oscar D. and Muthukumar, Thangamani and Nickerson, Deborah A. and O'Donnell, Christopher J. and Patel, Dinshaw J. and Patel, Tushar and Patton, James G. and Paul, Anu and Peskind, Elaine R. and Phelps, Mitch A. and Putterman, Chaim and Quesenberry, Peter J. and Quinn, Joseph F. and Raffai, Robert L. and Ranabothu, Saritha and Rao, Shannon Jiang and Rodriguez-Aguayo, Cristian and Rosenzweig, Anthony and Roth, Matthew E. and Rozowsky, Joel and Sabatine, Marc S. and Sakhanenko, Nikita A. and Saugstad, Julie Anne and Schmittgen, Thomas D. and Shah, Neethu and Shah, Ravi and Shedden, Kerby and Shi, Jian and Sood, Anil K. and Sopeyin, Anuoluwapo and Spengler, Ryan M. and Spetzler, Robert and Srinivasan, Srimeenakshi and Subramanian, Sai Lakshmi and Suthanthiran, Manikkam and Tanriverdi, Kahraman and Teng, Yun and Tewari, Muneesh and Thistlethwaite, William and Tuschl, Thomas and Urbanowicz, Karolina Kaczor and Vickers, Kasey C. and Voinnet, Olivier and Wang, Kai and Weaver, Alissa M. and Wei, Zhiyun and Weiner, Howard L. and Weiss, Zachary R. and Williams, Zev and Wong, David T. W. and Woodruff, Prescott G. and Xiao, Xinshu and Yan, Irene K. and Yeri, Ashish and Zhang, Bing and Zhang, Huang-Ge and Ansel, K. Mark and Breakefield, Xandra O. and Charest, Alain and Galas, David J. and Gerstein, Mark B. and McManus, Michael T. and Raffai, Robert L. and Roth, Matthew E. and Saugstad, Julie A. and Weaver, Alissa M. and Laurent, Louise C.},
	Da = {2019/04/04/},
	Date-Added = {2020-06-05 11:27:33 -0700},
	Date-Modified = {2020-06-05 11:27:33 -0700},
	Doi = {https://doi.org/10.1016/j.cell.2019.03.023},
	Isbn = {0092-8674},
	Journal = {Cell},
	Number = {2},
	Pages = {231--242},
	Title = {The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research},
	Ty = {JOUR},
	Url = {http://www.sciencedirect.com/science/article/pii/S0092867419302855},
	Volume = {177},
	Year = {2019},
	Bdsk-Url-1 = {http://www.sciencedirect.com/science/article/pii/S0092867419302855},
	Bdsk-Url-2 = {https://doi.org/10.1016/j.cell.2019.03.023}}

@article{Godoy:2019aa,
	Abstract = {Given the increasing interest in their use as disease biomarkers, the establishment of reproducible, accurate, sensitive, and specific platforms for microRNA (miRNA) quantification in biofluids is of high priority. We compare four platforms for these characteristics: small RNA sequencing (RNA-seq), FirePlex, EdgeSeq, and nCounter. For a pool of synthetic miRNAs, coefficients of variation for technical replicates are lower for EdgeSeq (6.9%) and RNA-seq (8.2%) than for FirePlex (22.4%); nCounter replicates are not performed. Receiver operating characteristic analysis for distinguishing present versus absent miRNAs shows small RNA-seq (area under curve 0.99) is superior to EdgeSeq (0.97), nCounter (0.94), and FirePlex (0.81). Expected differences in expression of placenta-associated miRNAs in plasma from pregnant and non-pregnant women are observed with RNA-seq and EdgeSeq, but not FirePlex or nCounter. These results indicate that differences in performance among miRNA profiling platforms impact ability to detect biological differences among samples and thus their relative utility for research and clinical use.},
	Address = {Division of Medical Oncology, Department of Medicine and Department of Developmental Biology, Washington University in Saint Louis, 4518 McKinley Ave., CB 8069, St. Louis, MO 63110, USA; Lung Biology Center, University of California, San Francisco, UCSF Box 2922, San Francisco, CA 94143, USA.; Lung Biology Center, University of California, San Francisco, UCSF Box 2922, San Francisco, CA 94143, USA.; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, 9500 Gilman Drive, Mail Code 0695, La Jolla, CA 92093-0695, USA; Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92037, USA.; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, 9500 Gilman Drive, Mail Code 0695, La Jolla, CA 92093-0695, USA; Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92037, USA.; Pacific Northwest Research Institute, 720 Broadway, Seattle, WA 98122, USA.; Pacific Northwest Research Institute, 720 Broadway, Seattle, WA 98122, USA.; Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA.; Lung Biology Center, University of California, San Francisco, UCSF Box 2922, San Francisco, CA 94143, USA; Cardiovascular Research Institute, University of California, San Francisco, UCSF Box 2922, San Francisco, CA 94143, USA.; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Diego, 9500 Gilman Drive, Mail Code 0695, La Jolla, CA 92093-0695, USA; Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92037, USA. Electronic address: llaurent@ucsd.edu.},
	Author = {Godoy, Paula M and Barczak, Andrea J and DeHoff, Peter and Srinivasan, Srimeenakshi and Etheridge, Alton and Galas, David and Das, Saumya and Erle, David J and Laurent, Louise C},
	Copyright = {Copyright {\copyright}2019 The Author(s). Published by Elsevier Inc. All rights reserved.},
	Crdt = {2019/12/19 06:00},
	Date = {2019 Dec 17},
	Date-Added = {2020-06-05 10:59:24 -0700},
	Date-Modified = {2020-06-05 10:59:24 -0700},
	Doi = {10.1016/j.celrep.2019.11.078},
	Edat = {2019/12/19 06:00},
	Gr = {U01 HL126496/HL/NHLBI NIH HHS/United States; UH3 TR000901/TR/NCATS NIH HHS/United States; U01 HL126493/HL/NHLBI NIH HHS/United States; U01 HL126494/HL/NHLBI NIH HHS/United States},
	Issn = {2211-1247 (Electronic)},
	Jid = {101573691},
	Journal = {Cell Rep},
	Jt = {Cell reports},
	Keywords = {*Abcam FirePlex; *HTG Molecular EdgeSeq; *NanoString nCounter; *extracellular RNA; *miRNA quantification; *small RNA-sequencing},
	Language = {eng},
	Lid = {S2211-1247(19)31569-4 {$[$}pii{$]$}; 10.1016/j.celrep.2019.11.078 {$[$}doi{$]$}},
	Lr = {20200528},
	Mhda = {2019/12/19 06:00},
	Month = {Dec},
	Number = {12},
	Oto = {NOTNLM},
	Own = {NLM},
	Pages = {4212--4222},
	Phst = {2019/06/05 00:00 {$[$}received{$]$}; 2019/10/17 00:00 {$[$}revised{$]$}; 2019/11/19 00:00 {$[$}accepted{$]$}; 2019/12/19 06:00 {$[$}entrez{$]$}; 2019/12/19 06:00 {$[$}pubmed{$]$}; 2019/12/19 06:00 {$[$}medline{$]$}},
	Pii = {S2211-1247(19)31569-4},
	Pl = {United States},
	Pmid = {31851944},
	Pst = {ppublish},
	Pt = {Journal Article; Research Support, N.I.H., Extramural},
	Sb = {IM},
	Status = {In-Process},
	Title = {Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms.},
	Volume = {29},
	Year = {2019},
	Bdsk-Url-1 = {https://doi.org/10.1016/j.celrep.2019.11.078}}

@article{Yeri:2018aa,
	Abstract = {Evolving interest in comprehensively profiling the full range of small RNAs present in small tissue biopsies and in circulating biofluids, and how the profile differs with disease, has launched small RNA sequencing (RNASeq) into more frequent use. However, known biases associated with small RNASeq, compounded by low RNA inputs, have been both a significant concern and a hurdle to widespread adoption. As RNASeq is becoming a viable choice for the discovery of small RNAs in low input samples and more labs are employing it, there should be benchmark datasets to test and evaluate the performance of new sequencing protocols and operators. In a recent publication from the National Institute of Standards and Technology, Pine et al., 2018, the investigators used a commercially available set of three tissues and tested performance across labs and platforms.},
	Author = {Yeri, Ashish and Courtright, Amanda and Danielson, Kirsty and Hutchins, Elizabeth and Alsop, Eric and Carlson, Elizabeth and Hsieh, Michael and Ziegler, Olivia and Das, Avash and Shah, Ravi V. and Rozowsky, Joel and Das, Saumya and Van Keuren-Jensen, Kendall},
	Da = {2018/05/05},
	Date-Added = {2020-06-05 10:59:17 -0700},
	Date-Modified = {2020-06-05 10:59:17 -0700},
	Doi = {10.1186/s12864-018-4726-6},
	Id = {Yeri2018},
	Isbn = {1471-2164},
	Journal = {BMC Genomics},
	Number = {1},
	Pages = {331},
	Title = {Evaluation of commercially available small RNASeq library preparation kits using low input RNA},
	Ty = {JOUR},
	Url = {https://doi.org/10.1186/s12864-018-4726-6},
	Volume = {19},
	Year = {2018},
	Bdsk-Url-1 = {https://doi.org/10.1186/s12864-018-4726-6}}

@article{Ran:2020aa,
	Abstract = {3566Background: Clinical biomarker studies are often hindered by the availability of tissue specimens of sufficient quality and quantity. While RNA-Seq is often considered the gold standard for measuring mRNA expression levels in cancer tissue, it typically requires multiple formalin-fixed paraffin-embedded (FFPE) tissue sections to extract a sufficient amount of quality RNA for subsequent gene expression profiling analysis. The HTG EdgeSeq technology is a gene expression profiling platform that combines quantitative nuclease protection assay technology with next-generation sequencing detection. Unlike RNA-Seq, the HTG EdgeSeq technology does not require RNA extraction, and can use small amounts of tissue material, typically several mm2, to generate reproducible gene expression profiles. Methods: This study compares the performance of RNA-Seq and HTG's profiling panel, the HTG EdgeSeq Precision Immuno-Oncology Panel (PIP), which is designed to measure expression levels of 1,392 genes focused on tumor/immune interaction. Approximately 1,200 samples from three tumor indications (gastric cancer, colorectal cancer and ovarian cancer) were tested using both technologies. Results: Up to four FFPE slides were used for RNA extraction to support RNA-Seq testing; out of the 1,202 samples processed, 1,099 generated extracted RNA of sufficient quality and quantity (as measured by RNA concentration, RIN score and {\%}DV200) to proceed to sequencing, which resulted in a pass rate of 91.4{\%} for RNA-Seq. The HTG EdgeSeq PIP panel resulted in a pass rate of 97.3{\%} (samples passing QC metrics) when the same 1,200 samples were tested, and required only a single FFPE section owing to the small sample requirement. The t-SNE (a non-linear dimensionality reduction method) analysis of the common 1,358 genes revealed similar clustering of the three cancer indications between the two methods. Correlations across individual genes by sample resulted in the mean Spearman correlation coefficient of 0.73 (95{\%} confidence interval of 0.61 - 0.80). Additionally, gene-wise comparisons across all samples were also evaluated. Conclusions: These data demonstrate that HTG EdgeSeq gene expression panels can be used as a competitive alternative to RNA-Seq, generating equivalent gene expression results, while offering the added benefits of a small sample size requirement, lack of RNA extraction bias, and fully automated data analysis pipeline.},
	Annote = {doi: 10.1200/JCO.2020.38.15{\_}suppl.3566},
	Author = {Ran, Di and Moharil, Janhavi and Lu, James and Gustafson, Heather and Culm-Merdek, Kerry and Strand-Tibbitts, Kristen and Benjamin, Laura and Navratil, Marian},
	Booktitle = {Journal of Clinical Oncology},
	Da = {2020/05/20},
	Date = {2020/05/20},
	Date-Added = {2020-06-05 07:18:02 -0700},
	Date-Modified = {2020-06-05 07:18:02 -0700},
	Doi = {10.1200/JCO.2020.38.15{\_}suppl.3566},
	Isbn = {0732-183X},
	Journal = {Journal of Clinical Oncology},
	Journal1 = {JCO},
	M3 = {doi: 10.1200/JCO.2020.38.15{\_}suppl.3566},
	Month = {2020/06/05},
	N2 = {3566Background: Clinical biomarker studies are often hindered by the availability of tissue specimens of sufficient quality and quantity. While RNA-Seq is often considered the gold standard for measuring mRNA expression levels in cancer tissue, it typically requires multiple formalin-fixed paraffin-embedded (FFPE) tissue sections to extract a sufficient amount of quality RNA for subsequent gene expression profiling analysis. The HTG EdgeSeq technology is a gene expression profiling platform that combines quantitative nuclease protection assay technology with next-generation sequencing detection. Unlike RNA-Seq, the HTG EdgeSeq technology does not require RNA extraction, and can use small amounts of tissue material, typically several mm2, to generate reproducible gene expression profiles. Methods: This study compares the performance of RNA-Seq and HTG's profiling panel, the HTG EdgeSeq Precision Immuno-Oncology Panel (PIP), which is designed to measure expression levels of 1,392 genes focused on tumor/immune interaction. Approximately 1,200 samples from three tumor indications (gastric cancer, colorectal cancer and ovarian cancer) were tested using both technologies. Results: Up to four FFPE slides were used for RNA extraction to support RNA-Seq testing; out of the 1,202 samples processed, 1,099 generated extracted RNA of sufficient quality and quantity (as measured by RNA concentration, RIN score and {\%}DV200) to proceed to sequencing, which resulted in a pass rate of 91.4{\%} for RNA-Seq. The HTG EdgeSeq PIP panel resulted in a pass rate of 97.3{\%} (samples passing QC metrics) when the same 1,200 samples were tested, and required only a single FFPE section owing to the small sample requirement. The t-SNE (a non-linear dimensionality reduction method) analysis of the common 1,358 genes revealed similar clustering of the three cancer indications between the two methods. Correlations across individual genes by sample resulted in the mean Spearman correlation coefficient of 0.73 (95{\%} confidence interval of 0.61 - 0.80). Additionally, gene-wise comparisons across all samples were also evaluated. Conclusions: These data demonstrate that HTG EdgeSeq gene expression panels can be used as a competitive alternative to RNA-Seq, generating equivalent gene expression results, while offering the added benefits of a small sample size requirement, lack of RNA extraction bias, and fully automated data analysis pipeline.},
	Number = {15{\_}suppl},
	Pages = {3566--3566},
	Publisher = {American Society of Clinical Oncology},
	Title = {Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens.},
	Ty = {JOUR},
	Url = {https://doi.org/10.1200/JCO.2020.38.15_suppl.3566},
	Volume = {38},
	Year = {2020},
	Year1 = {2020},
	Bdsk-Url-1 = {https://doi.org/10.1200/JCO.2020.38.15_suppl.3566},
	Bdsk-Url-2 = {https://doi.org/10.1200/JCO.2020.38.15%7B%5C_%7Dsuppl.3566}}

@article{Moura:2020aa,
	Author = {David Silva Moura, Nadia Hindi, Maria Lopez-Alvarez, Paloma Sanchez-Bustos, Irene Carrasco-Garcia, Paloma Santos-Fernandez, Paula Martinez-Delgado, Serena Lacerenza, Elena Blanco-Alcaina, Jose Lucinio Mondaza-Hernandez, Antonio Gutierrez, Rosa Maria Alvarez, Magda Cordeiro, Luis Miguel De Sande Gonz{\'a}lez, Gloria Marquina, Juana Maria Cano, Josefina Cruz Jurado, Claudia Maria Valverde Morales},
	Date-Added = {2020-06-04 17:54:12 -0700},
	Date-Modified = {2020-06-04 17:55:22 -0700},
	Journal = {ASCO Meeting},
	Title = {Immune-checkpoint genes as predictive biomarkers of trabectedin in advanced soft-tissue sarcoma (STS)},
	Year = {2020},
	Bdsk-File-1 = {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}}

@article{Orourke:2020aa,
	Author = {D. O'Rourke, J.F. Sanchez-Garcia, P. Rolfe, A. Huang, D. Wang J. Scheuenpflug, Z. Feng},
	Date-Added = {2020-06-04 15:18:15 -0700},
	Date-Modified = {2020-06-04 15:25:37 -0700},
	Journal = {American Association for Cancer Research (AACR) Virtual Annual Meeting 2020},
	Title = {Comparison of HTG-edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies},
	Year = {2020}}

@article{Inaki:2020aa,
	Author = {Koichiro Inaki, Naoyuki Maeda, Tomoko Shibutani, Serenella Eppenberger-Castori, Stefan Nicolet, Kumiko Koyama, Yui Tanaka, Yuki Kaneda, Kenichi Wakita, Yoshinobu Shiose, Masato Murakami.},
	Date-Added = {2020-06-04 15:02:32 -0700},
	Date-Modified = {2020-06-04 15:23:56 -0700},
	Journal = {American Association for Cancer Research (AACR) Virtual Annual Meeting 2020},
	Read = {1},
	Title = {Pan-cancer gene expression analysis of tissue microarray using EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis},
	Year = {2020},
	Bdsk-File-1 = {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}}

@article{Wang:2020aa,
	Abstract = {This study examined the role of the ubiquitin E3-ligase RNF123 in modulating downstream NF-ÎºB1 targets in glioblastoma (GB) tumor progression. Our findings revealed an oncogenic pathway (miR-155-5p-RNF123-NF-ÎºB1-p50-SerpinE1) that may represent a new therapeutic target pathway for GB patients with isocitrate dehydrogenase 1 and 2 (IDH) WT (wild type). Mechanistically, we demonstrated that RNF123 is downregulated in IDH WT GB patients and leads to the reduction of p50 levels. RNA-sequencing, reverse-phase protein arrays, and in vitro functional assays on IDH WT GB cell lines with RNF123 overexpression showed that SerpinE1 was a downstream target that is negatively regulated by RNF123. SERPINE1 knockdown reduced the proliferation and invasion of IDH WT GB cell lines. Both SerpinE1 and miR-155-5p overexpression negatively modulated RNF123 expression. In clinical translational analysis, RNF123, SerpinE1, and miR-155-5p were all associated with poor outcomes in GB patients. Multivariable analysis in IDH WT GB patients showed that concurrent low RNF123 and high SerpinE1 was an independent prognostic factor in predicting poor overall survival (p < 0.001, hazard ratio (HR) = 2.93, 95% confidence interval (CI) 1.7-5.05), and an increased risk of recurrence (p < 0.001, relative risk (RR) = 3.56, 95% CI 1.61-7.83).},
	Address = {Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; Department of Pathology, Cancer Hospital, Fudan University, Shanghai 200032, China.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; Medical Data Research Center, Providence Saint Joseph's Health, Portland, OR 97225, USA.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.; The David and Janet Polak Cancer and Vascular Biology Research Center, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Efron Street, Bat-Galim, Haifa 31096, Israel.; Pacific Neuroscience Institute, JWCI, Santa Monica, CA 90404, USA.; Department of Cell Development and Cancer Biology, Knight Cancer Institute, Portland, OR 97239, USA.; The David and Janet Polak Cancer and Vascular Biology Research Center, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Efron Street, Bat-Galim, Haifa 31096, Israel.; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China.; The Collaborative Innovation Center for Brain Science, Fudan University, Shanghai 200032, China.; Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.},
	Auid = {ORCID: 0000-0001-9625-1127},
	Author = {Wang, Xiaowen and Bustos, Matias A and Zhang, Xiaoqing and Ramos, Romela Irene and Tan, Cong and Iida, Yuuki and Chang, Shu-Ching and Salomon, Matthew P and Tran, Kevin and Gentry, Rebecca and Kravtsova-Ivantsiv, Yelena and Kelly, Daniel F and Mills, Gordon B and Ciechanover, Aaron and Mao, Ying and Hoon, Dave S B},
	Crdt = {2020/05/01 06:00},
	Date = {2020/04/27},
	Date-Added = {2020-06-04 14:23:56 -0700},
	Date-Modified = {2020-08-27 19:45:46 -0700},
	Dep = {20200427},
	Doi = {10.3390/cancers12051081},
	Edat = {2020/05/01 06:00},
	Gr = {N/A/Dr. Miriam and Sheldon G. Adelson Medical Research Foundation/; N/A/Gonda Foundation/; P30CA016672/NH/NIH HHS/United States},
	Issn = {2072-6694 (Print); 2072-6694 (Linking)},
	Jid = {101526829},
	Journal = {Cancers (Basel)},
	Jt = {Cancers},
	Keywords = {KPC1; NF-ÎºB pathway; PAI-1; miR-155; p50},
	Language = {eng},
	Lid = {E1081 {$[$}pii{$]$}; 10.3390/cancers12051081 {$[$}doi{$]$}},
	Lr = {20200430},
	Mhda = {2020/05/01 06:01},
	Month = {Apr},
	Number = {5},
	Oto = {NOTNLM},
	Own = {NLM},
	Phst = {2020/03/25 00:00 {$[$}received{$]$}; 2020/04/22 00:00 {$[$}revised{$]$}; 2020/04/25 00:00 {$[$}accepted{$]$}; 2020/05/01 06:00 {$[$}entrez{$]$}; 2020/05/01 06:00 {$[$}pubmed{$]$}; 2020/05/01 06:01 {$[$}medline{$]$}},
	Pii = {cancers12051081},
	Pl = {Switzerland},
	Pmid = {32349217},
	Pst = {epublish},
	Pt = {Journal Article},
	Status = {PubMed-not-MEDLINE},
	Title = {Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-KB1 Target SerpinE1 in Aggressive Glioblastoma Tumors.},
	Volume = {12},
	Year = {2020},
	Bdsk-Url-1 = {https://doi.org/10.3390/cancers12051081}}

@book{xie2015,
	Address = {Boca Raton, Florida},
	Author = {Yihui Xie},
	Edition = {2nd},
	Note = {ISBN 978-1498716963},
	Publisher = {Chapman and Hall/CRC},
	Title = {Dynamic Documents with {R} and knitr},
	Url = {http://yihui.org/knitr/},
	Year = {2015},
	Bdsk-Url-1 = {http://yihui.org/knitr/}}
